Search
Patexia Research
Case number 1:23-cv-00094

Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis, CO., LTD., > Documents

Date Field Doc. No.Description (Pages)
Oct 31, 2024 288 ORDER GRANTING MOTION TO WITHDRAW AS COUNSEL (ECF NO. 378 ). Ms. Anderson shall be TERMINATED as counsel of record in this matter. Signed by Chief District Judge Thomas S. Kleeh on 10/31/2024. Associated Cases: 1:24-md-03103-TSK-JPM et al. (snc) (Entered: 10/31/2024) (1)
Oct 30, 2024 287 MOTION to Withdraw as Attorney HAYLEE BERNAL ANDERSON'S MOTION TO WITHDRAW AS COUNSEL by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 10/30/2024) (4)
Oct 21, 2024 286 STIPULATION AND ORDER REGARDING CASE MANAGEMENT. Signed by Chief District Judge Thomas S. Kleeh on 10/21/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00089-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 10/21/2024) (7)
Oct 17, 2024 285 SUMMONS Returned Executed as to Samsung Bioepis, CO., LTD., served on 10/16/2024. (Pogue, David) (Entered: 10/17/2024) (2)
Oct 16, 2024 284 PROOF OF SERVICE filed by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM (Pogue, David) (Entered: 10/16/2024) (2)
Oct 15, 2024 283 STIPULATION and Proposed Order Regarding Case Management by Celltrion, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00089-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM(Gottlieb, Max) (Entered: 10/15/2024) (9)
Sep 30, 2024 281 ORDER DENYING DEFENDANT'S MOTIONS TO DISMISS. The Court DENIES WITHOUT PREJUDICE Defendant's motion (ECF No. 47 . Defendant is granted LEAVE TO REFILE its motion challenging jurisdiction after the Federal Circuit addresses the appeal of ECF No. 243. Any such refiled motion shall be filed within fifteen (15) days after the Federal Circuit issues its decision. Signed by Chief District Judge Thomas S. Kleeh on 09/30/2024. (snc) (Entered: 09/30/2024) (2)
Sep 30, 2024 282 ORDER GRANTING MOTIONS FOR ALTERNATIVE SERVICE. The following motions are GRANTED: Civil Action No. 1:23-CV-89, ECF No. 43 ; Civil Action No. 1:23-CV-94, ECF No. 38 ; and, Civil Action No. 1:23-CV-97, ECF No. 31. Signed by Chief District Judge Thomas S. Kleeh on 09/30/2024. (snc) (Entered: 09/30/2024) (8)
Sep 27, 2024 280 RESPONSE to Motion re (27 in 1:24-cv-00053-TSK, 334 in 1:24-md-03103-TSK-JPM, 261 in 1:23-cv-00106-TSK-JPM, 266 in 1:23-cv-00097-TSK-JPM, 254 in 1:24-cv-00039-TSK-JPM, 278 in 1:23-cv-00094-TSK-JPM, 215 in 1:23-cv-00089-TSK-JPM) MOTION for Status Conference filed by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 09/27/2024) (5)
Sep 16, 2024 279 ORDER of USCA for the Federal Circuit as to 259 Notice of Appeal filed by Samsung Bioepis Co., Ltd., 190 Notice of Appeal filed by BIOCON BIOLOGICS INC., Mylan Pharmaceuticals Inc., 258 Notice of Appeal filed by Samsung Bioepis, CO., LTD., 175 Notice of Appeal, filed by Samsung Bioepis, CO., LTD., 203 Notice of Appeal, filed by Formycon AG, 261 Notice of Appeal filed by Formycon AG, 176 Notice of Appeal, filed by Samsung Bioepis Co., Ltd. (snc) Modified to adjust filing date on 9/16/2024 (snc). (Entered: 09/16/2024) (3)
Sep 13, 2024 278 MOTION for Status Conference by Amgen, Inc., Celltrion, Inc., Formycon AG, Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Exhibit Ex. A, # 2 Exhibit Ex. B, # 3 Exhibit Ex. C, # 4 Exhibit Ex. D)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Gottlieb, Max) (Entered: 09/13/2024) () (8)
Sep 13, 2024 278 MOTION for Status Conference by Amgen, Inc., Celltrion, Inc., Formycon AG, Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Exhibit Ex. A, # 2 Exhibit Ex. B, # 3 Exhibit Ex. C, # 4 Exhibit Ex. D)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Gottlieb, Max) (Entered: 09/13/2024) (Exhibit Ex. A) (6)
Sep 13, 2024 278 MOTION for Status Conference by Amgen, Inc., Celltrion, Inc., Formycon AG, Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Exhibit Ex. A, # 2 Exhibit Ex. B, # 3 Exhibit Ex. C, # 4 Exhibit Ex. D)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Gottlieb, Max) (Entered: 09/13/2024) (Exhibit Ex. B) (18)
Sep 13, 2024 278 MOTION for Status Conference by Amgen, Inc., Celltrion, Inc., Formycon AG, Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Exhibit Ex. A, # 2 Exhibit Ex. B, # 3 Exhibit Ex. C, # 4 Exhibit Ex. D)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Gottlieb, Max) (Entered: 09/13/2024) (Exhibit Ex. C) (30)
Sep 13, 2024 278 MOTION for Status Conference by Amgen, Inc., Celltrion, Inc., Formycon AG, Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Exhibit Ex. A, # 2 Exhibit Ex. B, # 3 Exhibit Ex. C, # 4 Exhibit Ex. D)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Gottlieb, Max) (Entered: 09/13/2024) (Exhibit Ex. D) (12)
Sep 3, 2024 277 ORDER GRANTING MOTIONS TO WITHDRAW. For good cause, they are GRANTED (ECF Nos. 323 , 324 ). Renee M. Griffin and Yi Zhang shall be TERMINATED as counsel of record. Signed by Chief District Judge Thomas S. Kleeh on 09/03/2024. Associated Cases: 1:24-md-03103-TSK-JPM et al. (snc) (Entered: 09/03/2024) (1)
Aug 30, 2024 275 MOTION to Withdraw as Attorney RENEE M. GRIFFIN'S MOTION TO WITHDRAW AS COUNSEL by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 08/30/2024) (4)
Aug 30, 2024 276 MOTION to Withdraw as Attorney YI ZHANG'S MOTION TO WITHDRAW AS COUNSEL by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 08/30/2024) (4)
Aug 2, 2024 274 NOTICE by Regeneron Pharmaceuticals, Inc. of Judgments from the Patent and Trademark Office (Attachments: # 1 Attachment July 23, 2024 Order ('572 patent), # 2 Attachment July 30, 2024 Judgment ('601 patent))Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 08/02/2024) () (4)
Aug 2, 2024 274 NOTICE by Regeneron Pharmaceuticals, Inc. of Judgments from the Patent and Trademark Office (Attachments: # 1 Attachment July 23, 2024 Order ('572 patent), # 2 Attachment July 30, 2024 Judgment ('601 patent))Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 08/02/2024) (Attachment July 23, 2024 Order ('572 patent)) (6)
Aug 2, 2024 274 NOTICE by Regeneron Pharmaceuticals, Inc. of Judgments from the Patent and Trademark Office (Attachments: # 1 Attachment July 23, 2024 Order ('572 patent), # 2 Attachment July 30, 2024 Judgment ('601 patent))Associated Cases: 1:24-md-03103-TSK-JPM et al.(Pogue, David) (Entered: 08/02/2024) (Attachment July 30, 2024 Judgment ('601 patent)) (4)
Jul 16, 2024 273 USCA FOR THE FEDERAL CIRCUIT NOTICE OF APPELLATE CASE OPENING: re 258 in 1:24-md-03103-TSK-JPM and 268 in 1:23-cv-00094-TSK-JPM. Notice of Appeal filed by Samsung Bioepis, CO., LTD. Federal Circuit USCA Case Number: 2024-2083. (snc) (Entered: 07/16/2024) (4)
Jul 15, 2024 272 ORDER GRANTING MOTIONS FOR LEAVE TO FILE UNDER SEAL. The following motions to seal are GRANTED: ECF Nos. 262 , 264 . Signed by Chief District Judge Thomas S. Kleeh on 07/15/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 07/15/2024) (1)
Jul 12, 2024 269 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 07/12/2024) () (4)
Jul 12, 2024 271 Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 258 Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal, # 4 Final Order) Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM (snc) Modified on 7/12/2024 to correct docket number (snc). (Entered: 07/12/2024) () (1)
Jul 12, 2024 269 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 07/12/2024) (Attachment Memorandum in Support) (6)
Jul 12, 2024 269 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 07/12/2024) (Proposed Order) (1)
Jul 12, 2024 271 Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 258 Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal, # 4 Final Order) Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM (snc) Modified on 7/12/2024 to correct docket number (snc). (Entered: 07/12/2024) (Attorney List) (23)
Jul 12, 2024 271 Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 258 Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal, # 4 Final Order) Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM (snc) Modified on 7/12/2024 to correct docket number (snc). (Entered: 07/12/2024) (Docket Sheet) (30)
Jul 12, 2024 271 Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 258 Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal, # 4 Final Order) Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM (snc) Modified on 7/12/2024 to correct docket number (snc). (Entered: 07/12/2024) (Notice of Appeal) (3)
Jul 12, 2024 271 Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 258 Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal, # 4 Final Order) Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM (snc) Modified on 7/12/2024 to correct docket number (snc). (Entered: 07/12/2024) (Final Order) (3)
Jul 11, 2024 268 Notice of Appeal* (1)
Jul 10, 2024 267 ORDER FOR INJUNCTIVE RELIEF AGAINST SAMSUNG BIOEPIS. Signed by Chief District Judge Thomas S. Kleeh on 07/10/2024. (Copy to counsel for Regeneron and Samsung only) Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) Modified to unseal per TSK Chambers (rr) on 7/11/2024 (snc). (Entered: 07/10/2024) (3)
Jul 9, 2024 266 ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL (ECF NO. 243 ). Signed by Chief District Judge Thomas S. Kleeh on 07/09/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 07/09/2024) (1)
Jul 8, 2024 262 ORDER GRANTING MOTIONS FOR LEAVE TO FILE UNDER SEAL. The following motions to seal are GRANTED: ECF Nos. 227 , 229 , 234 . Signed by Chief District Judge Thomas S. Kleeh on 07/08/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00089-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM, 1:24-cv-00039-TSK-JPM (snc) (Entered: 07/08/2024) (1)
Jul 8, 2024 263 MOTION for Leave to File Under Seal by Samsung Bioepis, CO., LTD.,, Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 07/08/2024) () (3)
Jul 8, 2024 263 MOTION for Leave to File Under Seal by Samsung Bioepis, CO., LTD.,, Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 07/08/2024) (Attachment Memorandum in Support of Motion to Seal) (4)
Jul 3, 2024 259 REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) () (5)
Jul 3, 2024 260 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 07/03/2024) () (4)
Jul 3, 2024 259 REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 1) (3)
Jul 3, 2024 259 REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 2) (2)
Jul 3, 2024 259 REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 3) (3)
Jul 3, 2024 259 REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 4) (2)
Jul 3, 2024 259 REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 5) (4)
Jul 3, 2024 259 REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 6) (2)
Jul 3, 2024 259 REPLY to Response to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Labbe, John) (Entered: 07/03/2024) (Exhibit 7) (2)
Jul 3, 2024 260 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 07/03/2024) (Attachment Memorandum in Support) (6)
Jul 3, 2024 260 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 07/03/2024) (Proposed Order) (1)
Jul 2, 2024 258 ***SEALED***ORDER ESTABLISHING SECURITY UNDER FEDERAL RULE OF CIVIL PROCEDURE 65(c). Signed by Chief District Judge Thomas S. Kleeh on 07/02/2024. (Copy to counsel for Regeneron and Samsung only) Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 07/02/2024) (0)
Jun 28, 2024 257 USCA FOR THE FEDERAL CIRCUIT NOTICE OF APPELLATE CASE OPENING re (242 in 1:23-cv-00097-TSK-JPM, 203 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Formycon AG. USCA for the Federal Circuit USCA Case Number: 2024-2019. Case Manager: M. Ames. (Clerk confirmed with Federal Circuit (J. Phillips) that this second appeal was opened in error and that a termination letter would be issued.) (dk) (Entered: 07/01/2024) (4)
Jun 26, 2024 256 RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) () (8)
Jun 26, 2024 256 RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) (Exhibit 1) (5)
Jun 26, 2024 256 RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) (Exhibit 2) (7)
Jun 26, 2024 256 RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) (Exhibit 3) (6)
Jun 26, 2024 256 RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) (Exhibit 4) (3)
Jun 26, 2024 256 RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) (Exhibit 5) (4)
Jun 26, 2024 256 RESPONSE to Motion re (184 in 1:24-cv-00039-TSK-JPM, 239 in 1:23-cv-00094-TSK-JPM, 17 in 1:24-cv-00053-TSK, 186 in 1:23-cv-00089-TSK-JPM, 221 in 1:23-cv-00106-TSK-JPM, 796 in 1:22-cv-00061-TSK-JPM, 164 in 1:24-md-03103-TSK-JPM, 236 in 1:23-cv-00097-TSK-JPM) MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Ruby, Steven) (Entered: 06/26/2024) (Proposed Order) (4)
Jun 25, 2024 254 ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL (ECF NO. 200 ). Signed by Chief District Judge Thomas S. Kleeh on 06/25/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 06/25/2024) (1)
Jun 25, 2024 255 STIPULATION AND ORDER EXTENDING THE DEADLINE FOR SUBMISSION OF A PROPOSED ORDER ESTABLISHING SECURITY UNDER FED.R. CIV.P. 65(c). IT IS THEREFORE STIPULATED AND AGREED, that the parties' deadline to submit a Proposed Rule 65(c) Security Order(s) is extended to July l, 2024. Signed by Chief District Judge Thomas S. Kleeh on 06/25/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 06/25/2024) (4)
Jun 24, 2024 250 Redacted Order Granting Motions for Preliminary Injunction. Signed by Chief District Judge Thomas S. Kleeh on 06/14/2024. (Filed as public Order per Chambers (rr)) Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 06/24/2024) (30)
Jun 24, 2024 251 MOTION for Leave to File Under Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Memorandum of Law in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 06/24/2024) () (4)
Jun 24, 2024 253 STIPULATION AND [PROPOSED] ORDER EXTENDING THE DEADLINE FOR SUBMISSION OF A PROPOSED ORDER ESTABLISHING SECURITY UNDER FED. R. CIV. P. 65(c) by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 06/24/2024) (5)
Jun 24, 2024 251 MOTION for Leave to File Under Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Memorandum of Law in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 06/24/2024) (Memorandum of Law in Support) (6)
Jun 24, 2024 251 MOTION for Leave to File Under Seal by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Memorandum of Law in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 06/24/2024) (Proposed Order) (1)
Jun 20, 2024 248 USCA FOR THE FEDERAL CIRCUIT NOTICE OF APPELLATE CASE OPENING re 244 in 1:23-cv-00094-TSK-JPM, 175 in 1:24-md-03103-TSK-JPM) Notice of Appeal, filed by Samsung Bioepis, CO., LTD. Federal Circuit USCA Case Number: 2024-1966. (snc) (Entered: 06/20/2024) (4)
Jun 20, 2024 249 ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL (ECF NO. 180 ). Signed by Chief District Judge Thomas S. Kleeh on 06/20/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 06/20/2024) (1)
Jun 19, 2024 246 MOTION for Leave to File Under Seal by Samsung Bioepis, CO., LTD.,, Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 06/19/2024) () (3)
Jun 19, 2024 246 MOTION for Leave to File Under Seal by Samsung Bioepis, CO., LTD.,, Samsung Bioepis Co., Ltd.. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal)Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 06/19/2024) (Attachment Memorandum in Support of Motion to Seal) (4)
Jun 17, 2024 245 Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 175 Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal )Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM (snc) (Entered: 06/17/2024) () (1)
Jun 17, 2024 245 Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 175 Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal )Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM (snc) (Entered: 06/17/2024) (Attorney List) (23)
Jun 17, 2024 245 Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 175 Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal )Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM (snc) (Entered: 06/17/2024) (Docket Sheet) (30)
Jun 17, 2024 245 Transmission of Notice of Appeal and Docket Sheet to US Court of Appeals FEDERAL CIRCUIT re 175 Notice of Appeal. (Attachments: # 1 Attorney List, # 2 Docket Sheet, # 3 Notice of Appeal )Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM (snc) (Entered: 06/17/2024) (Notice of Appeal) (3)
Jun 14, 2024 240 ORDER DENYING MOTIONS TO STRIKE RELATING TO THE ATWAL DECLARATION (ECF NOS. 168 , 171 . Signed by Chief District Judge Thomas S. Kleeh on 06/14/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 06/14/2024) (5)
Jun 14, 2024 241 ***SEALED*** ORDER GRANTING MOTION FOR CLARIFICATION (ECF NO. 135 ). Signed by Chief District Judge Thomas S. Kleeh on 06/14/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM (Copy to counsel for Regeneron, Formycon and Samsung) (snc) (Entered: 06/14/2024) (0)
Jun 14, 2024 242 ORDER DENYING EMERGENCY MOTION TO STRIKE RELATING TO GRAHAM DECLARATION (ECF NO. [195-2]. Signed by Chief District Judge Thomas S. Kleeh on 06/14/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 06/14/2024) (4)
Jun 14, 2024 243 ***SEALED*** ORDER GRANTING MOTIONS FOR PRELIMINARY INJUNCTION. Signed by Chief District Judge Thomas S. Kleeh on 06/14/2024. Associated Cases: 1:24-md-03103-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (Copy ONLY to counsel for Regeneron and Samsung) (snc) (Entered: 06/14/2024) (0)
Jun 14, 2024 244 NOTICE OF APPEAL as to 243 Order on Motion to Seal, Order on Motion for Leave to File (Sealed) by Samsung Bioepis, CO., LTD. Filing fee $; 605, receipt number WVNDC-3961009. Appeal Record due by 7/15/2024. (Law, Sandra) Associated Cases: 1:24-md-03103-TSK-JPM (DN 175); 1:23-cv-00094 (DN 243). Modified to add document linkage on 6/17/2024 (dk). (Entered: 06/14/2024) (3)
Jun 12, 2024 239 MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) () (4)
Jun 12, 2024 239 MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Supplement Memo ISO) (8)
Jun 12, 2024 239 MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Proposed Order) (3)
Jun 12, 2024 239 MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Exhibit 1) (2)
Jun 12, 2024 239 MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Exhibit 2) (5)
Jun 12, 2024 239 MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Exhibit 3) (9)
Jun 12, 2024 239 MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Exhibit 4) (13)
Jun 12, 2024 239 MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Exhibit 5) (3)
Jun 12, 2024 239 MOTION Requiring Filing and Serving Redacted Versions of Sealed Filings by Amgen, Inc., Amgen, Inc.. (Attachments: # 1 Supplement Memo ISO, # 2 Proposed Order, # 3 Exhibit 1, # 4 Exhibit 2, # 5 Exhibit 3, # 6 Exhibit 4, # 7 Exhibit 5, # 8 Exhibit 6)Associated Cases: 1:24-md-03103-TSK-JPM et al.(Odell, Ashley) (Entered: 06/12/2024) (Exhibit 6) (5)
May 31, 2024 238 Other Document Joint Submission in Response to May 20, 2024 Order filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Appendix A - Regeneron's Filings, # 2 Appendix B - Amgen's Filings, # 3 Appendix C - Mylan/Biocon's Filings, # 4 Appendix D - Joint filings on behalf of Formycon, Celltrion, and Samsung Bioepis)Associated Cases: 1:24-md-03103-TSK et al.(Pogue, David) (Entered: 05/31/2024) () (14)
May 31, 2024 238 Other Document Joint Submission in Response to May 20, 2024 Order filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Appendix A - Regeneron's Filings, # 2 Appendix B - Amgen's Filings, # 3 Appendix C - Mylan/Biocon's Filings, # 4 Appendix D - Joint filings on behalf of Formycon, Celltrion, and Samsung Bioepis)Associated Cases: 1:24-md-03103-TSK et al.(Pogue, David) (Entered: 05/31/2024) (Appendix A - Regeneron's Filings) (30)
May 31, 2024 238 Other Document Joint Submission in Response to May 20, 2024 Order filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Appendix A - Regeneron's Filings, # 2 Appendix B - Amgen's Filings, # 3 Appendix C - Mylan/Biocon's Filings, # 4 Appendix D - Joint filings on behalf of Formycon, Celltrion, and Samsung Bioepis)Associated Cases: 1:24-md-03103-TSK et al.(Pogue, David) (Entered: 05/31/2024) (Appendix B - Amgen's Filings) (30)
May 31, 2024 238 Other Document Joint Submission in Response to May 20, 2024 Order filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Appendix A - Regeneron's Filings, # 2 Appendix B - Amgen's Filings, # 3 Appendix C - Mylan/Biocon's Filings, # 4 Appendix D - Joint filings on behalf of Formycon, Celltrion, and Samsung Bioepis)Associated Cases: 1:24-md-03103-TSK et al.(Pogue, David) (Entered: 05/31/2024) (Appendix C - Mylan/Biocon's Filings) (30)
May 31, 2024 238 Other Document Joint Submission in Response to May 20, 2024 Order filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Appendix A - Regeneron's Filings, # 2 Appendix B - Amgen's Filings, # 3 Appendix C - Mylan/Biocon's Filings, # 4 Appendix D - Joint filings on behalf of Formycon, Celltrion, and Samsung Bioepis)Associated Cases: 1:24-md-03103-TSK et al.(Pogue, David) (Entered: 05/31/2024) (Appendix D - Joint filings on behalf of Formycon, Celltrion, and Samsung Bioepis) (30)
May 30, 2024 237 ORDER EXTENDING TEMPORARY RESTRAINING ORDER: granting 236 , 218 and 149 Motions. Signed by Chief District Judge Thomas S. Kleeh on 05/30/2024. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 05/30/2024) (3)
May 29, 2024 236 MOTION for Extension of Temporary Restraining Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 05/29/2024) () (5)
May 29, 2024 236 MOTION for Extension of Temporary Restraining Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 05/29/2024) (Proposed Order) (3)
May 28, 2024 234 ORDER. Regeneron's Motion to Partially Withdraw Motions for Preliminary Injunction is GRANTED 119 . The portions of Regeneron's preliminary injunction motions that do not relate to the 865 patent are hereby WITHDRAWN. Amgen's motion for clarification on this issue is GRANTED 142 . The Court AMENDS the preliminary injunction briefing schedule with respect to Amgen. Signed by Chief District Judge Thomas S. Kleeh on 05/28/2024. Associated Cases: 1:24-md-03103-TSK et al. (snc) (Entered: 05/28/2024) (2)
May 28, 2024 235 STIPULATION AND ORDER TO SUPPLEMENT PRELIMINARY INJUNCTION RECORD. Signed by Chief District Judge Thomas S. Kleeh on 05/28/2024. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 05/28/2024) (13)
May 24, 2024 232 STIPULATION and proposed Order to Supplement Preliminary Injunction Record by Samsung Bioepis, CO., LTD.,, Samsung Bioepis Co., Ltd.. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 05/24/2024) (5)
May 24, 2024 233 STIPULATION and proposed Order to Supplement Preliminary Injunction Record (corrected to include Exhibit A) by Samsung Bioepis, CO., LTD.,, Samsung Bioepis Co., Ltd.. (Attachments: # 1 Exhibit A)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 05/24/2024) () (5)
May 24, 2024 233 STIPULATION and proposed Order to Supplement Preliminary Injunction Record (corrected to include Exhibit A) by Samsung Bioepis, CO., LTD.,, Samsung Bioepis Co., Ltd.. (Attachments: # 1 Exhibit A)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 05/24/2024) (Exhibit A) (8)
May 21, 2024 228 ORDER GRANTING MOTIONS FOR LEAVE TO FILE UNDER SEAL. The following motions to seal are GRANTED: ECF Nos. 22 , 100 , 101 . Signed by Chief District Judge Thomas S. Kleeh on 05/21/2024. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM, 1:24-cv-00039-TSK (snc) (Entered: 05/21/2024) (1)
May 21, 2024 229 ORDER REGARDING LIAISON COUNSEL. Signed by Chief District Judge Thomas S. Kleeh on 05/21/2024. Associated Cases: 1:24-md-03103-TSK et al. (snc) (Entered: 05/21/2024) (2)
May 21, 2024 230 ORDER DENYING CERTAIN MOTIONS AS MOOT. Regeneron's motion for guidance 36 and Amgen's motion requesting an expedited status conference 20 are DENIED AS MOOT. Signed by Chief District Judge Thomas S. Kleeh on 05/21/2024. Associated Cases: 1:24-md-03103-TSK et al. (snc) Modified to unseal on 5/21/2024; Order was sealed in error. NEF regen. (dk). (Entered: 05/21/2024) (1)
May 21, 2024 231 MOTION to Withdraw Motion to Partially Withdraw Motions for Preliminary Injunction by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00089-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 05/21/2024) (4)
May 20, 2024 227 ORDER. The parties are DIRECTED to file, on or before May 31, 2024, written proposals indicating which matters are appropriate for collective pretrial consideration and disposition while the case is designated as an MDL. Signed by Chief District Judge Thomas S. Kleeh on 5/20/2024. Associated Cases: 1:24-md-03103-TSK et al. (jb) (Entered: 05/20/2024) (1)
May 17, 2024 224 ORDER GRANTING MOTION FOR TEMPORARY RESTRAINING ORDER (ECF NO. 72 ). Signed by Chief District Judge Thomas S. Kleeh on 05/17/2024. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 05/17/2024) (4)
May 17, 2024 225 MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh, Scheduling Conference held on 5/17/2024. (Court Reporter Cindy Knecht) Associated Cases: 1:24-md-03103-TSK et al. (dk) (Entered: 05/17/2024) (0)
May 17, 2024 226 TRANSCRIPT of status conference held on 5/17/2024, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 6/7/2024. Redacted Transcript Deadline set for 6/17/2024. Release of Transcript Restriction set for 8/15/2024. Associated Cases: 1:24-md-03103-TSK et al.(ck) (Entered: 05/17/2024) (22)
May 16, 2024 221 ORDER GRANTING MOTION TO WITHDRAW APPEARANCES (ECF 181 , 163 ). The Clerk is DIRECTED to terminate J. Brett Milbourn and Joe Kronawitter of the law firm Horn Aylward & Bandy, LLC as limited appearance counsel for Plaintiff. Signed by Chief District Judge Thomas S Kleeh on 5/16/2024. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(dk) (Entered: 05/16/2024) (2)
May 16, 2024 222 MOTION for Leave to File Under Seal by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM(Law, Sandra) (Entered: 05/16/2024) () (4)
May 16, 2024 222 MOTION for Leave to File Under Seal by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM(Law, Sandra) (Entered: 05/16/2024) (Attachment Memorandum in Support of Motion to Seal) (4)
May 15, 2024 220 ORDER GRANTING 71 MOTION FOR LEAVE TO FILE UNDER SEAL. Signed by Chief District Judge Thomas S. Kleeh on 05/15/2024. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 05/15/2024) (2)
May 14, 2024 216 ***SEALED*** ORDER GRANTING MOTION TO SEAL (ECF NO. 40 ). Signed by Chief District Judge Thomas S. Kleeh on 05/14/2024. (Copy to counsel) Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM(snc) (Entered: 05/14/2024) (0)
May 14, 2024 217 ORDER GRANTING MOTION FOR LEAVE TO FILE INADVERTENTLY OMITTED EXHIBIT UNDER SEAL. Signed by Chief District Judge Thomas S. Kleeh on 05/14/2024. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(snc) (Entered: 05/14/2024) (2)
May 14, 2024 218 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 05/14/2024) () (5)
May 14, 2024 218 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 05/14/2024) (Attachment Memorandum in Support) (6)
May 14, 2024 218 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 05/14/2024) (Proposed Order) (2)
May 10, 2024 215 NOTICE by Regeneron Pharmaceuticals, Inc. Joint Notice of Pending Motions Associated Cases: 1:24-md-03103-TSK et al.(Ruby, Steven) (Entered: 05/10/2024) (14)
May 7, 2024 212 REPLY to Response to Motion re (207 in 1:23-cv-00094-TSK-JPM, 217 in 1:23-cv-00097-TSK-JPM, 168 in 1:23-cv-00089-TSK-JPM, 131 in 1:24-cv-00039-TSK, 754 in 1:22-cv-00061-TSK-JPM, 36 in 1:24-md-03103-TSK, 189 in 1:23-cv-00106-TSK-JPM) MOTION for Guidance Regarding Temporary Restraining Orders in View of the May 18, 2024 Expiration of Regulatory Exclusivity for Eylea filed by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK et al.(Ruby, Steven) (Entered: 05/07/2024) (4)
May 7, 2024 213 MOTION for Leave to File Inadvertently Omitted Exhibit UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Pogue, David) (Entered: 05/07/2024) () (5)
May 7, 2024 213 MOTION for Leave to File Inadvertently Omitted Exhibit UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM(Pogue, David) (Entered: 05/07/2024) (Proposed Order) (2)
May 6, 2024 210 Joint MOTION for Leave to File Under Seal by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 05/06/2024) () (4)
May 6, 2024 210 Joint MOTION for Leave to File Under Seal by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM(Law, Sandra) (Entered: 05/06/2024) (Attachment Memorandum in Support of Motion to Seal) (4)
May 5, 2024 208 RESPONSE to Motion re 207 MOTION for Guidance Regarding Temporary Restraining Orders in View of the May 18, 2024 Expiration of Regulatory Exclusivity for Eylea filed by Samsung Bioepis, CO., LTD.,. (Law, Sandra) (Entered: 05/05/2024) (7)
May 5, 2024 209 RESPONSE to Motion re (207 in 1:23-cv-00094-TSK-JPM, 36 in 1:24-md-03103-TSK) MOTION for Guidance Regarding Temporary Restraining Orders in View of the May 18, 2024 Expiration of Regulatory Exclusivity for Eylea filed by Samsung Bioepis, CO., LTD.,. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM(Law, Sandra) (Entered: 05/05/2024) (7)
May 3, 2024 207 MOTION for Guidance Regarding Temporary Restraining Orders in View of the May 18, 2024 Expiration of Regulatory Exclusivity for Eylea by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK et al.(Ruby, Steven) (Entered: 05/03/2024) (6)
Apr 30, 2024 206 ORDER 29 GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL. Signed by Chief District Judge Thomas S. Kleeh on 04/30/2024. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM (snc) (Entered: 04/30/2024) (2)
Apr 29, 2024 203 ***SEALED*** ORDER ADDRESSING PENDING MOTION TO SEAL (ECF NO. 200) Signed by Chief District Judge Thomas S Kleeh on 04/29/2024. (Copy emailed to counsel) Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM(snc) (Entered: 04/29/2024) (0)
Apr 29, 2024 204 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 04/29/2024) () (5)
Apr 29, 2024 204 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 04/29/2024) (Attachment Memorandum in Support) (7)
Apr 29, 2024 204 MOTION for Leave to File UNDER SEAL by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Proposed Order)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM(Ruby, Steven) (Entered: 04/29/2024) (Proposed Order) (2)
Apr 26, 2024 201 ORDER CANCELING STATUS CONFERENCES. On April 11, 2024, each of the cases became member cases of the MDL Case No. 1:24-md-3013. For that reason, the status conferences are CANCELED. Signed by Chief District Judge Thomas S. Kleeh on 4/26/2024. Associated Cases: 1:24-md-03103-TSK et al. (jb) (Entered: 04/26/2024) (1)
Apr 26, 2024 202 PRETRIAL ORDER #1: INITIAL SCHEDULING CONFERENCE. Scheduling Conference is set for 5/17/2024 11:00 AM by Zoom Videoconference before Chief District Judge Thomas S. Kleeh. Signed by Chief District Judge Thomas S. Kleeh on 4/26/2024. Associated Cases: 1:24-md-03103-TSK et al. (jb) (Entered: 04/26/2024) (10)
Apr 24, 2024 197 ORDER CONTINUING MAY 2, 2024 PERMANENT AND PRELIMINARY INJUNCTION HEARINGS. The Court will reschedule the preliminary and permanent injunction hearings, if necessary, by separate order. For reasons stated herein, the parties' Joint Motion for Status Conference Regarding the May 2, 2024 Permanent and Preliminary Injunction Hearings is also DENIED (ECF No. 9 ). Signed by Chief District Judge Thomas S Kleeh on 4/24/2024. Associated Cases: 1:24-md-03103-TSK et al. (dk) (Entered: 04/24/2024) (2)
Apr 24, 2024 198 ***SEALED*** ORDER ADDRESSING PENDING MOTIONS TO SEAL (ECF NOS. 194 , 195 ). Signed by Chief District Judge Thomas S Kleeh on 4/24/2024. (Copy to Counsel)Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM (dk) (Entered: 04/24/2024) (0)
Apr 24, 2024 199 ORDER GRANTING DEFENDANT'S MOTION FOR LEAVE TO FILE UNDER SEAL (ECF NOS. 153 , 172 ). The Clerk is DIRECTED to convert each motion to seal into the pleading that is attached. Signed by Chief District Judge Thomas S Kleeh on 4/24/2024. Associated Cases: 1:24-md-03103-TSK, 1:23-cv-00094-TSK-JPM, 1:23-cv-00106-TSK-JPM (dk) (Entered: 04/24/2024) (1)
Apr 23, 2024 196 Joint MOTION for Status Conference Regarding the May 2, 2024 Permanent and Preliminary Injunction Hearings by Regeneron Pharmaceuticals, Inc.. Associated Cases: 1:24-md-03103-TSK et al.(Pogue, David) (Entered: 04/23/2024) (9)
Apr 12, 2024 192 ***SEALED*** ORDER. Signed by Chief District Judge Thomas S Kleeh on 4/12/2024. (Emailed to Counsel) (dk) (Entered: 04/12/2024) (0)
Apr 11, 2024 190 NOTICE by Regeneron Pharmaceuticals, Inc. of Deposition of Peter Tessier (Ruby, Steven) (Entered: 04/11/2024) (4)
Apr 9, 2024 189 ORDER granting 187 Motion for Leave to Appear Pro Hac Vice of Lauren Martin. Signed by Chief District Judge Thomas S Kleeh on 4/9/2024. (mas) (Entered: 04/09/2024) (1)
Apr 8, 2024 182 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Notice of Deposition of Iain Cockburn. (Ruby, Steven) (Entered: 04/08/2024) (1)
Apr 8, 2024 183 NOTICE by Regeneron Pharmaceuticals, Inc. of Appearance of Jordan L. Damron (Franks, Raymond) (Entered: 04/08/2024) (2)
Apr 8, 2024 184 ***SEALED*** ORDER. Signed by Chief District Judge Thomas S. Kleeh on 4/8/2024. (jb) (Copy to counsel of record by email) (Entered: 04/08/2024) (0)
Apr 8, 2024 185 ***SEALED*** ORDER. Signed by Chief District Judge Thomas S Kleeh on 4/8/2024. Copy to Counsel of record.(cmd) (Entered: 04/08/2024) (0)
Apr 8, 2024 187 MOTION for Leave to Appear Pro Hac Vice of Lauren Martin by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Lauren Martin)(Law, Sandra) (Entered: 04/08/2024) () (2)
Apr 8, 2024 188 Pro Hac Vice filing fee in the amount of $200.00 paid for Lauren Martin. Receipt Number: 100003873. (jb) (Entered: 04/08/2024) (0)
Apr 8, 2024 187 MOTION for Leave to Appear Pro Hac Vice of Lauren Martin by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Lauren Martin)(Law, Sandra) (Entered: 04/08/2024) (Proposed Order Granting Motion for Pro Hac Vice Admission for Lauren Martin) (1)
Apr 4, 2024 181 MOTION to Withdraw Appearances of J. Brett Milbourn and Joe Kronawitter by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Entered: 04/04/2024) (4)
Apr 3, 2024 179 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Notice of Deposition of Denis Boyle. (Ruby, Steven) (Entered: 04/03/2024) (1)
Apr 2, 2024 178 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Notice of Deposition of Holly Prentice. (Ruby, Steven) (Entered: 04/02/2024) (1)
Apr 1, 2024 177 REPLY to Response to Motion re 171 Emergency MOTION to Strike Samsung Bioepis's and Formycon's Motion to Strike filed by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 04/01/2024) (6)
Mar 28, 2024 176 RESPONSE in Opposition re 171 Emergency MOTION to Strike Samsung Bioepis's and Formycon's Motion to Strike filed by Samsung Bioepis, CO., LTD.,. (Taylor, Chad) (Entered: 03/28/2024) (6)
Mar 27, 2024 175 ORDER granting 173 Motion for Leave to Appear Pro Hac Vice for Mary Charlotte Y. Carroll filed by Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S. Kleeh on 3/27/2024. (jb) (Entered: 03/27/2024) (1)
Mar 26, 2024 173 MOTION for Leave to Appear Pro Hac Vice of Mary Charlotte Y. Carroll by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/26/2024) () (2)
Mar 26, 2024 174 Pro Hac Vice filing fee in the amount of $200.00 paid for Mary Charlotte Y. Carroll. Receipt Number: 100003866. (jb) (Entered: 03/26/2024) (0)
Mar 26, 2024 173 MOTION for Leave to Appear Pro Hac Vice of Mary Charlotte Y. Carroll by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/26/2024) (Exhibit A-WVSB Receipt) (2)
Mar 26, 2024 173 MOTION for Leave to Appear Pro Hac Vice of Mary Charlotte Y. Carroll by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/26/2024) (Attachment A) (1)
Mar 26, 2024 173 MOTION for Leave to Appear Pro Hac Vice of Mary Charlotte Y. Carroll by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/26/2024) (Attachment B) (1)
Mar 26, 2024 173 MOTION for Leave to Appear Pro Hac Vice of Mary Charlotte Y. Carroll by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/26/2024) (Proposed Order) (1)
Mar 22, 2024 167 ***SEALED*** ORDER. Signed by Chief District Judge Thomas S. Kleeh on 3/22/2024. (jb) (Copy to counsel of record by email) (Entered: 03/22/2024) (0)
Mar 22, 2024 169 ***SEALED*** ORDER. Signed by Chief District Judge Thomas S Kleeh on 3/22/2024. Copy to counsel. (cmd) (Entered: 03/22/2024) (0)
Mar 22, 2024 170 ***SEALED*** ORDER. Signed by Chief District Judge Thomas S Kleeh on 3/22/2024. Copy to counsel.(cmd) (Entered: 03/22/2024) (0)
Mar 22, 2024 171 Emergency MOTION to Strike Samsung Bioepis's and Formycon's Motion to Strike by Regeneron Pharmaceuticals, Inc.. (Ruby, Steven) (Entered: 03/22/2024) (7)
Mar 21, 2024 160 ORDER granting 155 MOTION for Leave to Appear Pro Hac Vice of Alyssa J. Picard. Signed by Chief District Judge Thomas S Kleeh on 3/21/2024. (mas) (Entered: 03/21/2024) (1)
Mar 21, 2024 161 ORDER granting 156 MOTION for Leave to Appear Pro Hac Vice of Sven E. Henningson III. Signed by Chief District Judge Thomas S Kleeh on 3/21/2024. (mas) (Entered: 03/21/2024) (1)
Mar 21, 2024 162 ORDER granting 157 MOTION for Leave to Appear Pro Hac Vice of Grace W. Knofczynski. Signed by Chief District Judge Thomas S Kleeh on 3/21/2024. (mas) (Entered: 03/21/2024) (1)
Mar 21, 2024 164 DEFENDANT SAMSUNG BIOEPIS CO., LTD.S OPPOSITION TO 118 REGENERON PHARMACEUTICALS, INC.S MOTION FOR A PRELIMINARY INJUNCTION by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal, # 2 Attachment Samsung Bioepis Opposition to Preliminary Injunction, # 3 Attachment Clark Declaration, # 4 Exhibit 1 to Clark Declaration, # 5 Exhibit 2 to Clark Declaration, # 6 Exhibit 3 to Clark Declaration, # 7 Exhibit 4 to Clark Declaration, # 8 Exhibit 5 to Clark Declaration, # 9 Exhibit 6 to Clark Declaration, # 10 Exhibit 7 to Clark Declaration, # 11 Attachment Boyle Declaration, # 12 Exhibit A to Boyle Declaration, # 13 Exhibit 1 to Boyle Declaration, # 14 Exhibit 2 to Boyle Declaration, # 15 Exhibit 3 to Boyle Declaration, # 16 Exhibit 4 to Boyle Declaration, # 17 Exhibit 5 to Boyle Declaration, # 18 Exhibit 6 to Boyle Declaration, # 19 Exhibit 7 to Boyle Declaration, # 20 Exhibit 8 to Boyle Declaration, # 21 Exhibit 9 to Boyle Declaration, # 22 Exhibit 10 to Boyle Declaration, # 23 Exhibit 11 to Boyle Declaration, # 24 Exhibit 12 to Boyle Declaration, # 25 Exhibit 13 to Boyle Declaration, # 26 Exhibit 14 to Boyle Declaration, # 27 Exhibit 15 to Boyle Declaration, # 28 Exhibit 16 to Boyle Declaration, # 29 Exhibit 17 to Boyle Declaration, # 30 Exhibit 18 to Boyle Declaration, # 31 Exhibit 19 to Boyle Declaration, # 32 Exhibit 20 to Boyle Declaration, # 33 Attachment Tessier Declaration, # 34 Exhibit A to Tessier Declaration, # 35 Exhibit 1 to Tessier Declaration, # 36 Exhibit 2 to Tessier Declaration, # 37 Exhibit 3 to Tessier Declaration, # 38 Exhibit 4 to Tessier Declaration, # 39 Exhibit 5 to Tessier Declaration, # 40 Exhibit 6 to Tessier Declaration, # 41 Exhibit 7 to Tessier Declaration, # 42 Exhibit 8 to Tessier Declaration, # 43 Exhibit 9 to Tessier Declaration, # 44 Exhibit 10 to Tessier Declaration, # 45 Exhibit 11 to Tessier Declaration, # 46 Exhibit 12 to Tessier Declaration, # 47 Exhibit 13 to Tessier Declaration, # 48 Exhibit 14 to Tessier Declaration, # 49 Exhibit 15 to Tessier Declaration, # 50 Exhibit 16 to Tessier Declaration, # 51 Exhibit 17 to Tessier Declaration, # 52 Exhibit 18 to Tessier Declaration, # 53 Exhibit 19 to Tessier Declaration, # 54 Exhibit 20 to Tessier Declaration, # 55 Exhibit 21 to Tessier Declaration, # 56 Exhibit 22 to Tessier Declaration, # 57 Exhibit 23 to Tessier Declaration, # 58 Exhibit 24 to Tessier Declaration, # 59 Exhibit 25 to Tessier Declaration, # 60 Exhibit 26 to Tessier Declaration, # 61 Exhibit 27 to Tessier Declaration, # 62 Exhibit 28 to Tessier Declaration, # 63 Exhibit 29 to Tessier Declaration, # 64 Exhibit 30 to Tessier Declaration, # 65 Exhibit 31 to Tessier Declaration, # 66 Exhibit 32 to Tessier Declaration, # 67 Exhibit 33 to Tessier Declaration, # 68 Exhibit 34 to Tessier Declaration, # 69 Exhibit 35 to Tessier Declaration, # 70 Exhibit 36 to Tessier Declaration, # 71 Exhibit 37 to Tessier Declaration, # 72 Exhibit 38 to Tessier Declaration, # 73 Exhibit 39 to Tessier Declaration, # 74 Exhibit 40 to Tessier Declaration, # 75 Exhibit 41 to Tessier Declaration, # 76 Exhibit 42 to Tessier Declaration, # 77 Exhibit 43 to Tessier Declaration, # 78 Exhibit 44 to Tessier Declaration, # 79 Exhibit 45 to Tessier Declaration, # 80 Exhibit 46 to Tessier Declaration, # 81 Exhibit 47 to Tessier Declaration, # 82 Exhibit 48 to Tessier Declaration, # 83 Exhibit 49 to Tessier Declaration, # 84 Exhibit 50 to Tessier Declaration, # 85 Exhibit 51 to Tessier Declaration, # 86 Exhibit 52 to Tessier Declaration, # 87 Exhibit 53 to Tessier Declaration, # 88 Exhibit 54 to Tessier Declaration, # 89 Exhibit 55 to Tessier Declaration, # 90 Exhibit 56 to Tessier Declaration)(Law, Sandra) Modified on 3/22/2024 (cmd). Modified on 3/22/2024 (cmd). Modified on 3/22/2024 (cmd). (Entered: 03/21/2024) (0)
Mar 21, 2024 165 Responsive Declaration of Iain Cockburn, Ph.D. by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal, # 2 Attachment Cockburn Declaration to Samsung Bioepis Opposition to Preliminary Injunction, # 3 Exhibit 1 to Cockburn Declaration, # 4 Exhibit 2 to Cockburn Declaration, # 5 Exhibit 3 to Cockburn Declaration, # 6 Exhibit 4 to Cockburn Declaration, # 7 Exhibit 5 to Cockburn Declaration, # 8 Exhibit 6 (part 1) to Cockburn Declaration, # 9 Exhibit 6 (part 2) to Cockburn Declaration, # 10 Exhibit 7 to Cockburn Declaration, # 11 Exhibit 8 to Cockburn Declaration, # 12 Exhibit 9 to Cockburn Declaration, # 13 Exhibit 10 to Cockburn Declaration, # 14 Exhibit 11 to Cockburn Declaration, # 15 Exhibit 12 to Cockburn Declaration, # 16 Exhibit 13 to Cockburn Declaration, # 17 Exhibit 14 to Cockburn Declaration, # 18 Exhibit 15 to Cockburn Declaration, # 19 Exhibit 16 to Cockburn Declaration, # 20 Exhibit 17 to Cockburn Declaration, # 21 Exhibit 18 to Cockburn Declaration, # 22 Exhibit 19 to Cockburn Declaration, # 23 Exhibit 20 to Cockburn Declaration, # 24 Exhibit 21 to Cockburn Declaration, # 25 Exhibit 22 to Cockburn Declaration, # 26 Exhibit 23 (part 1) to Cockburn Declaration, # 27 Exhibit 23 (part 2) to Cockburn Declaration, # 28 Exhibit 23 (part 3) to Cockburn Declaration, # 29 Exhibit 23 (part 4) to Cockburn Declaration, # 30 Exhibit 23 (part 5) to Cockburn Declaration, # 31 Exhibit 23 (part 6) to Cockburn Declaration, # 32 Exhibit 23 (part 7) to Cockburn Declaration, # 33 Exhibit 23 (part 8) to Cockburn Declaration, # 34 Exhibit 23 (part 9) to Cockburn Declaration, # 35 Exhibit 24 to Cockburn Declaration, # 36 Exhibit 25 to Cockburn Declaration, # 37 Exhibit 26 to Cockburn Declaration, # 38 Exhibit 27 to Cockburn Declaration, # 39 Exhibit 28 to Cockburn Declaration, # 40 Exhibit 29 to Cockburn Declaration, # 41 Exhibit 30 to Cockburn Declaration, # 42 Exhibit 31 (part 1) to Cockburn Declaration, # 43 Exhibit 31 (part 2) to Cockburn Declaration, # 44 Exhibit 31 (part 3) to Cockburn Declaration, # 45 Exhibit 32 to Cockburn Declaration, # 46 Exhibit 33 to Cockburn Declaration, # 47 Exhibit 34 to Cockburn Declaration, # 48 Exhibit 35 to Cockburn Declaration, # 49 Exhibit 36 to Cockburn Declaration, # 50 Exhibit 37 to Cockburn Declaration, # 51 Exhibit 38 to Cockburn Declaration, # 52 Exhibit 39 to Cockburn Declaration, # 53 Exhibit 40 to Cockburn Declaration, # 54 Exhibit 41 to Cockburn Declaration, # 55 Exhibit 42 to Cockburn Declaration, # 56 Exhibit 43 to Cockburn Declaration, # 57 Exhibit 44 to Cockburn Declaration, # 58 Exhibit 45 to Cockburn Declaration, # 59 Exhibit 46 to Cockburn Declaration, # 60 Exhibit 47 to Cockburn Declaration, # 61 Exhibit 48 to Cockburn Declaration, # 62 Exhibit 49 to Cockburn Declaration, # 63 Exhibit 50 to Cockburn Declaration, # 64 Exhibit 51 (part 1) to Cockburn Declaration, # 65 Exhibit 51 (part 2) to Cockburn Declaration, # 66 Exhibit 51 (part 3) to Cockburn Declaration, # 67 Exhibit 51 (part 4) to Cockburn Declaration, # 68 Exhibit 51 (part 5) to Cockburn Declaration, # 69 Exhibit 51 (part 6) to Cockburn Declaration, # 70 Exhibit 51 (part 7) to Cockburn Declaration, # 71 Exhibit 51 (part 8) to Cockburn Declaration, # 72 Exhibit 51 (part 9) to Cockburn Declaration, # 73 Exhibit 51 (part 10) to Cockburn Declaration, # 74 Exhibit 51 (part 11) to Cockburn Declaration, # 75 Exhibit 51 (part 12) to Cockburn Declaration, # 76 Exhibit 51 (part 13) to Cockburn Declaration, # 77 Exhibit 51 (part 14) to Cockburn Declaration, # 78 Exhibit 51 (part 15) to Cockburn Declaration, # 79 Exhibit 51 (part 16) to Cockburn Declaration, # 80 Exhibit 51 (part 17) to Cockburn Declaration, # 81 Exhibit 51 (part 18) to Cockburn Declaration, # 82 Exhibit 51 (part 19) to Cockburn Declaration, # 83 Exhibit 51 (part 20) to Cockburn Declaration, # 84 Exhibit 51 (part 21) to Cockburn Declaration, # 85 Exhibit 51 (part 22) to Cockburn Declaration, # 86 Exhibit 52 to Cockburn Declaration, # 87 Exhibit 53 to Cockburn Declaration, # 88 Exhibit 54 to Cockburn Declaration, # 89 Exhibit 55 to Cockburn Declaration, # 90 Exhibit 56 to Cockburn Declaration, # 91 Exhibit 57 to Cockburn Declaration, # 92 Exhibit 58 to Cockburn Declaration, # 93 Exhibit 59 to Cockburn Declaration, # 94 Exhibit 60 to Cockburn Declaration, # 95 Exhibit 61 to Cockburn Declaration, # 96 Exhibit 62 to Cockburn Declaration, # 97 Exhibit 63 to Cockburn Declaration, # 98 Exhibit 64 to Cockburn Declaration, # 99 Exhibit 65 to Cockburn Declaration, # 100 Exhibit 66 to Cockburn Declaration, # 101 Exhibit 67 to Cockburn Declaration, # 102 Exhibit 68 to Cockburn Declaration, # 103 Exhibit 69 to Cockburn Declaration, # 104 Exhibit 70 to Cockburn Declaration, # 105 Exhibit 71 to Cockburn Declaration, # 106 Exhibit 72 to Cockburn Declaration, # 107 Exhibit 73 to Cockburn Declaration, # 108 Exhibit 74 to Cockburn Declaration, # 109 Exhibit 75 to Cockburn Declaration, # 110 Exhibit 76 to Cockburn Declaration, # 111 Exhibit 77 to Cockburn Declaration, # 112 Exhibit 78 to Cockburn Declaration, # 113 Exhibit 79 to Cockburn Declaration, # 114 Exhibit 80 to Cockburn Declaration, # 115 Exhibit 81 to Cockburn Declaration, # 116 Exhibit 82 to Cockburn Declaration, # 117 Exhibit 83 to Cockburn Declaration, # 118 Exhibit 84 (part 1) to Cockburn Declaration, # 119 Exhibit 84 (part 2) to Cockburn Declaration, # 120 Exhibit 84 (part 3) to Cockburn Declaration, # 121 Exhibit 84 (part 4) to Cockburn Declaration, # 122 Exhibit 85 to Cockburn Declaration, # 123 Exhibit 86 to Cockburn Declaration, # 124 Exhibit 87 to Cockburn Declaration, # 125 Exhibit 88 to Cockburn Declaration, # 126 Exhibit 89 to Cockburn Declaration, # 127 Exhibit 90 to Cockburn Declaration, # 128 Exhibit 91 (part 1) to Cockburn Declaration, # 129 Exhibit 91 (part 2) to Cockburn Declaration, # 130 Exhibit 91 (part 3) to Cockburn Declaration, # 131 Exhibit 92 to Cockburn Declaration, # 132 Exhibit 93 to Cockburn Declaration, # 133 Exhibit 94 to Cockburn Declaration, # 134 Exhibit 95 to Cockburn Declaration, # 135 Exhibit 96 to Cockburn Declaration, # 136 Exhibit 97 to Cockburn Declaration, # 137 Exhibit 98 to Cockburn Declaration, # 138 Exhibit 99 to Cockburn Declaration, # 139 Exhibit 100 to Cockburn Declaration, # 140 Exhibit 101 to Cockburn Declaration, # 141 Exhibit 102 to Cockburn Declaration, # 142 Exhibit 103 to Cockburn Declaration, # 143 Exhibit 104 to Cockburn Declaration, # 144 Exhibit 105 to Cockburn Declaration, # 145 Exhibit 106 to Cockburn Declaration, # 146 Exhibit 107 to Cockburn Declaration, # 147 Exhibit 108 to Cockburn Declaration, # 148 Exhibit 109 to Cockburn Declaration, # 149 Exhibit 110 to Cockburn Declaration, # 150 Exhibit 111 to Cockburn Declaration, # 151 Exhibit 112 (part 1) to Cockburn Declaration, # 152 Exhibit 112 (part 2) to Cockburn Declaration, # 153 Exhibit 112 (part 3) to Cockburn Declaration, # 154 Exhibit 112 (part 4) to Cockburn Declaration, # 155 Exhibit 113 to Cockburn Declaration, # 156 Exhibit 114 to Cockburn Declaration, # 157 Exhibit 115 to Cockburn Declaration, # 158 Exhibit 116 to Cockburn Declaration, # 159 Exhibit 117 (part 1) to Cockburn Declaration, # 160 Exhibit 117 (part 2) to Cockburn Declaration, # 161 Exhibit 118 to Cockburn Declaration, # 162 Exhibit 119 to Cockburn Declaration, # 163 Exhibit 120 to Cockburn Declaration, # 164 Exhibit 121 to Cockburn Declaration, # 165 Exhibit 122 to Cockburn Declaration, # 166 Index 123 to Cockburn Declaration, # 167 Exhibit 124 to Cockburn Declaration, # 168 Exhibit 125 to Cockburn Declaration, # 169 Exhibit 126 to Cockburn Declaration, # 170 Exhibit 127 to Cockburn Declaration, # 171 Exhibit 128 to Cockburn Declaration, # 172 Exhibit 129 to Cockburn Declaration, # 173 Exhibit 130 to Cockburn Declaration, # 174 Exhibit 131 to Cockburn Declaration, # 175 Exhibit 132 (part 1) to Cockburn Declaration, # 176 Exhibit 132 (part 2) to Cockburn Declaration, # 177 Exhibit 132 (part 3) to Cockburn Declaration, # 178 Exhibit 133 (part 1) to Cockburn Declaration, # 179 Exhibit 133 (part 2) to Cockburn Declaration, # 180 Exhibit 133 (part 3) to Cockburn Declaration, # 181 Exhibit 134 (part 1) to Cockburn Declaration, # 182 Exhibit 134 (part 2) to Cockburn Declaration, # 183 Exhibit 135 (part 1) to Cockburn Declaration, # 184 Exhibit 135 (part 2) to Cockburn Declaration, # 185 Exhibit 135 (part 3) to Cockburn Declaration, # 186 Exhibit 136 to Cockburn Declaration, # 187 Exhibit 137 (part 1) to Cockburn Declaration, # 188 Exhibit 137 (part 2) to Cockburn Declaration, # 189 Exhibit 138 to Cockburn Declaration, # 190 Exhibit 139 to Cockburn Declaration, # 191 Exhibit 140 to Cockburn Declaration, # 192 Exhibit 141 to Cockburn Declaration)(Law, Sandra) Modified on 3/22/2024 (cmd). (Entered: 03/21/2024) (0)
Mar 21, 2024 166 Responsive Declaration of Dr. Holly Prentice, Ph.D. by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Seal, # 2 Attachment Prentice Declaration, # 3 Exhibit 1 to Prentice Declaration, # 4 Exhibit 2 to Prentice Declaration, # 5 Exhibit 3 to Prentice Declaration, # 6 Exhibit 4 to Prentice Declaration, # 7 Exhibit 5 to Prentice Declaration, # 8 Exhibit 6 to Prentice Declaration, # 9 Exhibit 7 to Prentice Declaration, # 10 Exhibit 8 to Prentice Declaration, # 11 Exhibit 9 to Prentice Declaration, # 12 Exhibit 10 to Prentice Declaration, # 13 Exhibit 11 to Prentice Declaration, # 14 Exhibit 12 to Prentice Declaration, # 15 Exhibit 13 to Prentice Declaration, # 16 Exhibit 14 to Prentice Declaration, # 17 Exhibit 15 to Prentice Declaration, # 18 Exhibit 16 to Prentice Declaration, # 19 Exhibit 17 to Prentice Declaration, # 20 Exhibit 18 to Prentice Declaration, # 21 Exhibit 19 to Prentice Declaration, # 22 Exhibit 20 to Prentice Declaration, # 23 Exhibit 21 to Prentice Declaration, # 24 Exhibit 22 to Prentice Declaration, # 25 Exhibit 23 to Prentice Declaration, # 26 Exhibit 24 to Prentice Declaration, # 27 Exhibit 25 to Prentice Declaration, # 28 Exhibit 26 to Prentice Declaration, # 29 Exhibit 27 to Prentice Declaration, # 30 Exhibit 28 to Prentice Declaration, # 31 Exhibit 29 to Prentice Declaration, # 32 Exhibit 30 to Prentice Declaration, # 33 Exhibit 31 to Prentice Declaration, # 34 Exhibit 32 to Prentice Declaration, # 35 Exhibit 33 to Prentice Declaration, # 36 Exhibit 34 to Prentice Declaration, # 37 Exhibit 35 to Prentice Declaration, # 38 Exhibit 36 to Prentice Declaration, # 39 Exhibit 37 to Prentice Declaration, # 40 Exhibit 38 to Prentice Declaration, # 41 Exhibit 39 to Prentice Declaration, # 42 Exhibit 40 to Prentice Declaration, # 43 Exhibit 41 to Prentice Declaration, # 44 Exhibit 42 to Prentice Declaration, # 45 Exhibit 43 to Prentice Declaration, # 46 Exhibit 44 to Prentice Declaration, # 47 Exhibit 45 to Prentice Declaration, # 48 Exhibit 46 to Prentice Declaration, # 49 Exhibit 47 to Prentice Declaration, # 50 Exhibit 48 to Prentice Declaration, # 51 Exhibit 49 to Prentice Declaration, # 52 Exhibit 50 to Prentice Declaration, # 53 Exhibit 51 to Prentice Declaration, # 54 Exhibit 52 to Prentice Declaration, # 55 Exhibit 53 to Prentice Declaration, # 56 Exhibit 54 to Prentice Declaration, # 57 Exhibit 55 to Prentice Declaration, # 58 Exhibit 56 to Prentice Declaration, # 59 Exhibit 57 to Prentice Declaration, # 60 Exhibit 58 to Prentice Declaration, # 61 Exhibit 59 to Prentice Declaration, # 62 Exhibit 60 to Prentice Declaration, # 63 Exhibit 61 to Prentice Declaration)(Law, Sandra) Modified on 3/22/2024 (cmd). (Entered: 03/21/2024) (0)
Mar 18, 2024 158 ORDER granting 151 Motion of Abigail Clark for Leave to Appear Pro Hac Vice on behalf of Samsung Bioepis, Co., Ltd. Signed by Chief District Judge Thomas S Kleeh on 3/18/2024. (dk) (Entered: 03/18/2024) (1)
Mar 18, 2024 159 Pro Hac Vice Filing Fee in the amount of $600.00 paid for Alyssa J. Picard, Sven E. Henningson, III & Grace W. Knofczynski. Receipt Number: 100003857. (jb) (Entered: 03/18/2024) (0)
Mar 15, 2024 155 MOTION for Leave to Appear Pro Hac Vice of Alyssa J. Picard by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) () (2)
Mar 15, 2024 156 MOTION for Leave to Appear Pro Hac Vice of Sven E. Henningson III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) () (2)
Mar 15, 2024 157 MOTION for Leave to Appear Pro Hac Vice of Grace W. Knofczynski by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) () (5)
Mar 15, 2024 156 MOTION for Leave to Appear Pro Hac Vice of Sven E. Henningson III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Exhibit A-WVSB Receipt) (2)
Mar 15, 2024 156 MOTION for Leave to Appear Pro Hac Vice of Sven E. Henningson III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Attachment A) (1)
Mar 15, 2024 156 MOTION for Leave to Appear Pro Hac Vice of Sven E. Henningson III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Attachment B) (1)
Mar 15, 2024 156 MOTION for Leave to Appear Pro Hac Vice of Sven E. Henningson III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Proposed Order) (1)
Mar 15, 2024 157 MOTION for Leave to Appear Pro Hac Vice of Grace W. Knofczynski by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Exhibit A-WVSB Receipt) (2)
Mar 15, 2024 157 MOTION for Leave to Appear Pro Hac Vice of Grace W. Knofczynski by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Attachment A) (1)
Mar 15, 2024 157 MOTION for Leave to Appear Pro Hac Vice of Grace W. Knofczynski by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Attachment B) (1)
Mar 15, 2024 157 MOTION for Leave to Appear Pro Hac Vice of Grace W. Knofczynski by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Proposed Order) (1)
Mar 15, 2024 155 MOTION for Leave to Appear Pro Hac Vice of Alyssa J. Picard by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Exhibit A-WVSB Receipt) (2)
Mar 15, 2024 155 MOTION for Leave to Appear Pro Hac Vice of Alyssa J. Picard by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Attachment A) (1)
Mar 15, 2024 155 MOTION for Leave to Appear Pro Hac Vice of Alyssa J. Picard by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Attachment B) (1)
Mar 15, 2024 155 MOTION for Leave to Appear Pro Hac Vice of Alyssa J. Picard by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-WVSB Receipt, # 2 Attachment A, # 3 Attachment B, # 4 Proposed Order)(Ruby, Steven) (Entered: 03/15/2024) (Proposed Order) (1)
Mar 14, 2024 153 ORDER GRANTING MOTION 152 TO WITHDRAW EMERGENCY MOTION TO COMPEL. For the reasons stated in Defendant's Motion 152 to Withdraw, said Motion is GRANTED. Defendant's Emergency Motion 148 to Compel is TERMINATED AS MOOT. Signed by Magistrate Judge James P. Mazzone on 03/14/2024. (snc) (Entered: 03/14/2024) (1)
Mar 14, 2024 154 Pro Hac Vice Filing fee: $ 200.00, receipt number 100003848. (For attorney Abigail Clark) (snc) (Entered: 03/14/2024) (0)
Mar 13, 2024 151 MOTION for Leave to Appear Pro Hac Vice for Abigail Clark by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order)(Law, Sandra) (Entered: 03/13/2024) () (2)
Mar 13, 2024 152 MOTION to Withdraw 148 Emergency MOTION to Compel as Moot by Samsung Bioepis, CO., LTD.,. (Taylor, Chad) (Entered: 03/13/2024) (3)
Mar 13, 2024 151 MOTION for Leave to Appear Pro Hac Vice for Abigail Clark by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order)(Law, Sandra) (Entered: 03/13/2024) (Proposed Order) (1)
Mar 12, 2024 149 ORDER OF REFERRAL: 148 Emergency MOTION to Compel filed by Samsung Bioepis, CO., LTD., (Copy provided to Referral Judge as directed). Signed by Chief District Judge Thomas S Kleeh on 3/12/2024. (mas) (Entered: 03/12/2024) (1)
Mar 12, 2024 150 ORDER DIRECTING RESPONSE re 148 Emergency MOTION to Compel. Plaintiff is DIRECTED to file a response brief on or before March 13, 2024, at 5:00pm. Responses due by 3/13/2024. Signed by Magistrate Judge James P. Mazzone on 3/12/2024. (hrc) (Entered: 03/12/2024) (1)
Mar 11, 2024 146 ***SEALED*** ORDER. Signed by Chief District Judge Thomas S. Kleeh on 3/11/2024. (jb) (Sealed per TSK) (Copy to counsel of record by email) (Entered: 03/11/2024) (0)
Mar 11, 2024 148 Emergency MOTION to Compel by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) () (2)
Mar 11, 2024 148 Emergency MOTION to Compel by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Attachment Memorandum in Support of Motion to Compel) (18)
Mar 11, 2024 148 Emergency MOTION to Compel by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 1 to Memorandum in Support of Motion to Compel) (7)
Mar 11, 2024 148 Emergency MOTION to Compel by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 2 to Memorandum in Support of Motion to Compel) (7)
Mar 11, 2024 148 Emergency MOTION to Compel by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 3 to Memorandum in Support of Motion to Compel) (30)
Mar 11, 2024 148 Emergency MOTION to Compel by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 4 to Memorandum in Support of Motion to Compel) (15)
Mar 11, 2024 148 Emergency MOTION to Compel by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 5 to Memorandum in Support of Motion to Compel) (6)
Mar 11, 2024 148 Emergency MOTION to Compel by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 6 to Memorandum in Support of Motion to Compel) (6)
Mar 11, 2024 148 Emergency MOTION to Compel by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 7 to Memorandum in Support of Motion to Compel) (3)
Mar 11, 2024 148 Emergency MOTION to Compel by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 8 to Memorandum in Support of Motion to Compel) (30)
Mar 11, 2024 148 Emergency MOTION to Compel by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 9 to Memorandum in Support of Motion to Compel) (4)
Mar 11, 2024 148 Emergency MOTION to Compel by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 10 to Memorandum in Support of Motion to Compel) (6)
Mar 11, 2024 148 Emergency MOTION to Compel by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 11 to Memorandum in Support of Motion to Compel) (3)
Mar 11, 2024 148 Emergency MOTION to Compel by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 12 to Memorandum in Support of Motion to Compel) (16)
Mar 11, 2024 148 Emergency MOTION to Compel by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Attachment Memorandum in Support of Motion to Compel, # 2 Exhibit 1 to Memorandum in Support of Motion to Compel, # 3 Exhibit 2 to Memorandum in Support of Motion to Compel, # 4 Exhibit 3 to Memorandum in Support of Motion to Compel, # 5 Exhibit 4 to Memorandum in Support of Motion to Compel, # 6 Exhibit 5 to Memorandum in Support of Motion to Compel, # 7 Exhibit 6 to Memorandum in Support of Motion to Compel, # 8 Exhibit 7 to Memorandum in Support of Motion to Compel, # 9 Exhibit 8 to Memorandum in Support of Motion to Compel, # 10 Exhibit 9 to Memorandum in Support of Motion to Compel, # 11 Exhibit 10 to Memorandum in Support of Motion to Compel, # 12 Exhibit 11 to Memorandum in Support of Motion to Compel, # 13 Exhibit 12 to Memorandum in Support of Motion to Compel, # 14 Exhibit 13 to Memorandum in Support of Motion to Compel)(Law, Sandra) (Entered: 03/11/2024) (Exhibit 13 to Memorandum in Support of Motion to Compel) (2)
Mar 8, 2024 145 CERTIFICATE OF SERVICE by Samsung Bioepis, CO., LTD., for the Notices of Deposition for Dr. Bernhardt Trout and Dr. Ranjit Singh Atwal. (Law, Sandra) (Entered: 03/08/2024) (3)
Mar 6, 2024 140 MOTION for Leave to Supplement Opposition to Defendants' Motion Regarding Non-Party Discovery by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1 - Regeneron's Supplemental Opposition to Defendants' Motion Regarding Non-Party Discovery)(Pogue, David) (Entered: 03/06/2024) () (5)
Mar 6, 2024 141 ORDER GRANTING REGENERON'S MOTION FOR LEAVE TO SUPPLEMENT OPPOSITION [ECF NO. 140 ]. Regeneron's Supplemental Opposition to Defendants' Motion Regarding Non-Party Discovery [ECF No. 140-1] shall be SEPARATELY FILED. Signed by Chief District Judge Thomas S. Kleeh on 3/6/2024. (jb) (Entered: 03/06/2024) (1)
Mar 6, 2024 142 REGENERON'S SUPPLEMENTAL OPPOSITION TO DEFENDANT'S MOTION REGARDING NON-PARTY DISCOVERY filed by Regeneron Pharmaceuticals, Inc. (Filed per 141 Order) (jb) Modified on 3/11/2024 to Create relationship to document #135 (ag). (Entered: 03/06/2024) (6)
Mar 6, 2024 143 CERTIFICATE OF SERVICE by Samsung Bioepis, CO., LTD., for the Notice of Deposition of Dr. Sean Sheridan. (Law, Sandra) (Entered: 03/06/2024) (3)
Mar 6, 2024 140 MOTION for Leave to Supplement Opposition to Defendants' Motion Regarding Non-Party Discovery by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1 - Regeneron's Supplemental Opposition to Defendants' Motion Regarding Non-Party Discovery)(Pogue, David) (Entered: 03/06/2024) (Exhibit 1 - Regeneron's Supplemental Opposition to Defendants' Motion) (6)
Mar 5, 2024 138 ***SEALED*** ORDER. Signed by Chief District Judge Thomas S. Kleeh on 3/5/2024. (jb) (Copy to counsel of record by email) (Entered: 03/05/2024) (0)
Mar 4, 2024 132 ***SEALED***ORDER. Signed by Chief District Judge Thomas S. Kleeh on 3/4/2024. (jb) (Copy to counsel of record by email) (Entered: 03/04/2024) (0)
Mar 4, 2024 134 ***SEALED***ORDER. Signed by Chief District Judge Thomas S. Kleeh on 3/4/2024. (jb) (Copy to counsel of record by email) (Main Document 134 replaced on 3/4/2024 with corrected order) (jb). (Entered: 03/04/2024) (0)
Mar 4, 2024 136 ***SEALED*** ORDER. Signed by Chief District Judge Thomas S. Kleeh on 3/4/2024. (jb) (Copy to counsel of record by email) (Main Document 136 replaced on 3/4/2024 with corrected order) (jb). (Entered: 03/04/2024) (0)
Feb 29, 2024 128 NOTICE of Appearance by Michael W. Carey on behalf of Regeneron Pharmaceuticals, Inc. (Carey, Michael) (Entered: 02/29/2024) (2)
Feb 27, 2024 124 ORDER ***SEALED***. Signed by Chief District Judge Thomas S. Kleeh on 2/27/2024. (jb) (Copy of order to counsel of record by email) (Entered: 02/27/2024) (0)
Feb 27, 2024 126 ORDER ***SEALED***. Signed by Chief District Judge Thomas S. Kleeh on 2/27/2024. (jb) (Copy to counsel of record by email) (Entered: 02/27/2024) (0)
Feb 23, 2024 119 ***SEALED*** ORDER. Signed by Chief District Judge Thomas S Kleeh on 2/23/2024. Copy emailed to counsel.(cmd) (Entered: 02/23/2024) (0)
Feb 23, 2024 120 STIPULATED PROTECTIVE ORDER. Signed by Chief District Judge Thomas S Kleeh on 02/23/2024. (snc) (Entered: 02/23/2024) (30)
Feb 22, 2024 114 STIPULATION and Joint Request for Entry of Agreed Protective Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)(Pogue, David) (Entered: 02/22/2024) () (5)
Feb 22, 2024 115 TRANSCRIPT of status conference held on 2/15/2024, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 3/14/2024. Redacted Transcript Deadline set for 3/25/2024. Release of Transcript Restriction set for 5/22/2024. (ck) (Entered: 02/22/2024) (11)
Feb 22, 2024 116 CERTIFICATE OF SERVICE by Samsung Bioepis, CO., LTD., for Defendant Samsung Bioepis Co. Ltd.'s Production of Documents Bates SB150004915 to SB150005395. (Law, Sandra) (Entered: 02/22/2024) (4)
Feb 22, 2024 117 CERTIFICATE OF SERVICE by Samsung Bioepis, CO., LTD., for Defendant Samsung Bioepis Co. Ltd.'s Production of Documents Bates SB150005396 to SB150005434. (Law, Sandra) (Entered: 02/22/2024) (4)
Feb 22, 2024 118 MOTION FOR PRELIMINARY INJUNCTION AND INCORPORATED MEMORANDUM OF LAW by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Motion for Preliminary Injunction, # 3 Attachment Opening Brief In Support of Motion for Preliminary Injunction, # 4 Exhibit Trout Declaration, part 1, # 5 Exhibit Trout Declaration, part 2, # 6 Exhibit Trout Declaration, part 3, # 7 Exhibit Trout Declaration, part 4, # 8 Exhibit Trout Declaration, part 5, # 9 Exhibit Trout Declaration, part 6, # 10 Exhibit Trout Declaration, part 7, # 11 Exhibit Trout Declaration, part 8, # 12 Exhibit Trout Declaration, part 9, # 13 Exhibit Trout Declaration, part 10, # 14 Exhibit Trout Declaration, part 11, # 15 Exhibit Atwal Declaration, part 1, # 16 Exhibit Atwal Declaration, part 2, # 17 Exhibit Atwal Declaration, part 3, # 18 Exhibit Atwal Declaration, part 4, # 19 Exhibit Atwal Declaration, part 5, # 20 Exhibit Atwal Declaration, part 6, # 21 Exhibit Atwal Declaration, part 7, # 22 Exhibit Atwal Declaration, part 8, # 23 Exhibit Atwal Declaration, part 9, # 24 Exhibit Atwal Declaration, part 10, # 25 Exhibit Atwal Declaration, part 11, # 26 Exhibit Sheridan Declaration, part 1, # 27 Exhibit Sheridan Declaration, part 2, # 28 Exhibit Sheridan Declaration, part 3, # 29 Exhibit Sheridan Declaration, part 4, # 30 Exhibit Sheridan Declaration, part 5, # 31 Exhibit Sheridan Declaration, part 6, # 32 Exhibit Sheridan Declaration, part 7, # 33 Exhibit Sheridan Declaration, part 8, # 34 Exhibit Sheridan Declaration, part 9, # 35 Exhibit Sheridan Declaration, part 10, # 36 Exhibit Sheridan Declaration, part 11, # 37 Exhibit Sheridan Declaration, part 12, # 38 Exhibit Sheridan Declaration, part 13, # 39 Exhibit Clark Declaration, # 40 Exhibit Patel Declaration, # 41 Proposed Order)(Pogue, David) Modified on 2/23/2024 (cmd). (Entered: 02/22/2024) (0)
Feb 22, 2024 114 STIPULATION and Joint Request for Entry of Agreed Protective Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)(Pogue, David) (Entered: 02/22/2024) (Proposed Order) (30)
Feb 20, 2024 112 ***SEALED*** ORDER. Signed by Chief District Judge Thomas S Kleeh on 2/20/2024. Copy to Counsel.(cmd) (Entered: 02/20/2024) (0)
Feb 20, 2024 113 PLAINTIFF REGENERON PHARMACEUTICALS, INC.S MEMORANDUM OF LAW IN OPPOSITION 47 MOTION to Dismiss for Lack of Jurisdiction Pursuant to Fed. R. Civ. P. 12(b)(2) filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3 part 1, # 4 Exhibit 3 part 2, # 5 Exhibit 4, # 6 Exhibit 5, # 7 Exhibit 6, # 8 Exhibit 7, # 9 Exhibit 8, # 10 Exhibit 9, # 11 Exhibit 10, # 12 Exhibit 11)(cmd) (Entered: 02/20/2024) (0)
Feb 15, 2024 107 MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh: Status Conference held on 2/15/2024. (Court Reporter Cindy Knecht) (jb) (Entered: 02/15/2024) (0)
Feb 15, 2024 108 ORDER FOLLOWING STATUS CONFERENCE. Plaintiff Regeneron Pharmaceuticals, Inc.'s Emergency Motion for Clarification of the Courts January 9, 2024 Order [ECF NO. 96 ] is DENIED. Plaintiff is ORDERED to file separate response briefings to the Defendants' motions to dismiss. Defendants joint anticipatory request to file surreply briefing to plaintiffs preliminary injunction motions is DENIED WITHOUT PREJUDICE. Signed by Chief District Judge Thomas S Kleeh on 2/15/2024. (jb) (Entered: 02/15/2024) (2)
Feb 15, 2024 109 AMENDED BRIEFING SCHEDULE ON MOTIONS TO DISMISS AND AMENDED SCHEDULE FOR PRELIMINARY INJUNCTION PROCEEDINGS. Regeneron shall file individual responses tothe motions to dismiss on or before 2/19/2024. Replies due by 2/26/2024. Regeneron is to file individual motions for preliminary injunction by 2/22/2024. Hearing on Rengeron's motions for preliminary injunction is set for 5/2/2024 10:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Status Conference set for 5/13/2024 12:00 PM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 2/15/2024. (jb) (Entered: 02/15/2024) (4)
Feb 15, 2024 110 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Notice of Service of Subpoena. (Pogue, David) (Entered: 02/15/2024) (2)
Feb 14, 2024 102 Pro Hac Vice Filing Fee for J. Brett Milbourn and Joe Kronawitter in the amount of $400 paid. Receipt Number 100003835. (jb) (Entered: 02/14/2024) (0)
Feb 14, 2024 103 ORDER granting 99 Motion for Leave to Appear Pro Hac Vice as to Joe Kronawitter. Signed by Chief District Judge Thomas S Kleeh on 2/14/2024. (mas) (Entered: 02/14/2024) (1)
Feb 14, 2024 104 ORDER granting 98 Motion for Leave to Appear Pro Hac Vice for J. Brett Milbourn filed by Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 2/14/2024. (jb) (Entered: 02/14/2024) (1)
Feb 14, 2024 105 RESPONSE to Motion re 96 Emergency MOTION for Clarification of the Court's January 9, 2024 Order filed by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Exhibit A)(Law, Sandra) (Entered: 02/14/2024) () (9)
Feb 14, 2024 106 RESPONSE in Opposition re 100 MOTION to Expedite Status Conference filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Ruby, Steven) (Entered: 02/14/2024) () (10)
Feb 14, 2024 105 RESPONSE to Motion re 96 Emergency MOTION for Clarification of the Court's January 9, 2024 Order filed by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Exhibit A)(Law, Sandra) (Entered: 02/14/2024) (Exhibit A) (29)
Feb 14, 2024 106 RESPONSE in Opposition re 100 MOTION to Expedite Status Conference filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Ruby, Steven) (Entered: 02/14/2024) (Exhibit 1) (28)
Feb 14, 2024 106 RESPONSE in Opposition re 100 MOTION to Expedite Status Conference filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Ruby, Steven) (Entered: 02/14/2024) (Exhibit 2) (30)
Feb 14, 2024 106 RESPONSE in Opposition re 100 MOTION to Expedite Status Conference filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Ruby, Steven) (Entered: 02/14/2024) (Exhibit 3) (30)
Feb 14, 2024 106 RESPONSE in Opposition re 100 MOTION to Expedite Status Conference filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Ruby, Steven) (Entered: 02/14/2024) (Exhibit 4) (3)
Feb 14, 2024 106 RESPONSE in Opposition re 100 MOTION to Expedite Status Conference filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Ruby, Steven) (Entered: 02/14/2024) (Exhibit 5) (4)
Feb 14, 2024 106 RESPONSE in Opposition re 100 MOTION to Expedite Status Conference filed by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Ruby, Steven) (Entered: 02/14/2024) (Exhibit 6) (4)
Feb 13, 2024 96 Emergency MOTION for Clarification of the Court's January 9, 2024 Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Pogue, David) (Entered: 02/13/2024) () (9)
Feb 13, 2024 97 ORDER directing responses, if any, to Plaintiff Regeneron Pharmaceuticals, Inc.'s Emergency Motion for Clarification of the Court's January 9, 2024 Order [ECF NO. 96 ] be filed on or before February 15, 2024. Signed by Chief District Judge Thomas S Kleeh on 2/13/2024. (jb) (Entered: 02/13/2024) (2)
Feb 13, 2024 98 MOTION for Leave to Appear Pro Hac Vice of J. Brett Milbourn by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 02/13/2024) () (2)
Feb 13, 2024 99 MOTION for Leave to Appear Pro Hac Vice of Joe Kronawitter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 02/13/2024) () (2)
Feb 13, 2024 100 MOTION to Expedite Status Conference by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Law, Sandra) (Entered: 02/13/2024) () (8)
Feb 13, 2024 101 ORDER ON DEFENDANTS' EXPEDITED MOTION FOR STATUS CONFERENCE. Motion to Expedite Status Conference [ECF NO. 100 ] filed by Samsung Bioepis, CO., LTD is GRANTED. A Status Conference is set for 2/15/2024 11:30 AM by ZoomGov before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 2/13/2024. (jb) (Entered: 02/13/2024) (2)
Feb 13, 2024 99 MOTION for Leave to Appear Pro Hac Vice of Joe Kronawitter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 02/13/2024) (Attachment WVSB Receipt) (2)
Feb 13, 2024 99 MOTION for Leave to Appear Pro Hac Vice of Joe Kronawitter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 02/13/2024) (Proposed Order) (1)
Feb 13, 2024 100 MOTION to Expedite Status Conference by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Law, Sandra) (Entered: 02/13/2024) (Exhibit A) (2)
Feb 13, 2024 100 MOTION to Expedite Status Conference by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Law, Sandra) (Entered: 02/13/2024) (Exhibit B) (9)
Feb 13, 2024 100 MOTION to Expedite Status Conference by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Law, Sandra) (Entered: 02/13/2024) (Exhibit C) (3)
Feb 13, 2024 98 MOTION for Leave to Appear Pro Hac Vice of J. Brett Milbourn by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 02/13/2024) (Attachment WVSB Receipt) (2)
Feb 13, 2024 98 MOTION for Leave to Appear Pro Hac Vice of J. Brett Milbourn by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment WVSB Receipt, # 2 Proposed Order)(Ruby, Steven) (Entered: 02/13/2024) (Proposed Order) (1)
Feb 13, 2024 96 Emergency MOTION for Clarification of the Court's January 9, 2024 Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Pogue, David) (Entered: 02/13/2024) (Exhibit A) (17)
Feb 13, 2024 96 Emergency MOTION for Clarification of the Court's January 9, 2024 Order by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Pogue, David) (Entered: 02/13/2024) (Exhibit B) (9)
Feb 2, 2024 94 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron Pharmaceuticals, Inc.'s Objections and Responses to Samsung Bioepis Co., Ltd.'s First Set of Requests for Production to Regeneron (Nos. 1-39). (Pogue, David) (Entered: 02/02/2024) (2)
Feb 2, 2024 95 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron's Identification of Patents. (Pogue, David) (Entered: 02/02/2024) (2)
Jan 31, 2024 93 ORDER APPROVING APPLICATIONS TO APPEAR PRO HAC VICE as to Rhochelle Krawetz, Arthur J. Argall III and Teagan Gregory. Signed by Chief District Judge Thomas S Kleeh on 1/31/2024. (jb) (Entered: 01/31/2024) (1)
Jan 30, 2024 92 Pro Hac Vice filing fee paid in the amount of $600.00 for Rhochelle Krawetz, Arthur J. Argall III & Teagan Gregory. Receipt Number: 100003822. (jb) (Entered: 01/30/2024) (0)
Jan 29, 2024 91 ORDER. With respect to Regeneron's omnibus response to the motions to dismiss, Regeneron is permitted to submit a filing up to 40 pages in length. Signed by Chief District Judge Thomas S Kleeh on 1/29/2024. (jb) (Entered: 01/29/2024) (2)
Jan 28, 2024 89 CERTIFICATE OF SERVICE by Samsung Bioepis, CO., LTD., for Samsung Bioepis Co., Ltd.'s Objections and Responses to Regeneron Pharmaceutical Inc.'s First Set of Requests for Production. (Law, Sandra) (Entered: 01/28/2024) (3)
Jan 28, 2024 90 CERTIFICATE OF SERVICE by Samsung Bioepis, CO., LTD., for Samsung Bioepis Co., Ltd.'s Production of Documents Bates Numbered SB150001336 to SB150004914. (Law, Sandra) (Entered: 01/28/2024) (3)
Jan 25, 2024 88 ORDER GRANTING 87 JOINT MOTION TO PERMIT PARTIES' LOCAL COUNSEL TO ATTEND DEPOSITIONS BY TELEPHONE OR OTHER ELECTRONIC MEANS. Signed by Chief District Judge Thomas S Kleeh on 1/25/2024. (dk) (Entered: 01/25/2024) (1)
Jan 24, 2024 87 Joint MOTION Leave for Local Counsel to attend depositions by phone by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order)(Taylor, Chad) (Entered: 01/24/2024) () (6)
Jan 24, 2024 87 Joint MOTION Leave for Local Counsel to attend depositions by phone by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order)(Taylor, Chad) (Entered: 01/24/2024) (Proposed Order) (1)
Jan 23, 2024 85 Pro Hac Vice filing fee in the amount of $200.00 for Matthew D. Robson is paid. Receipt Number 100003814. (jb) (Entered: 01/23/2024) (0)
Jan 23, 2024 86 ORDER granting 83 Motion for Leave to Appear Pro Hac Vice for Matthew D. Robson filed by Samsung Bioepis, CO., LTD. Signed by Chief District Judge Thomas S Kleeh on 1/23/2024. (jb) (Entered: 01/23/2024) (1)
Jan 22, 2024 83 MOTION for Leave to Appear Pro Hac Vice of Matthew D. Robson by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Matthew D. Robson)(Law, Sandra) (Entered: 01/22/2024) () (2)
Jan 22, 2024 84 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron's Notice of Service of Subpoena. (Pogue, David) (Entered: 01/22/2024) (2)
Jan 22, 2024 83 MOTION for Leave to Appear Pro Hac Vice of Matthew D. Robson by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Matthew D. Robson)(Law, Sandra) (Entered: 01/22/2024) (Proposed Order Granting Motion for Pro Hac Vice Admission for Matthew D. Robson) (1)
Jan 19, 2024 78 MOTION for Leave to Appear Pro Hac Vice of Arthur J. Argall III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) () (2)
Jan 19, 2024 79 MOTION for Leave to Appear Pro Hac Vice of Teagan Gregory by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) () (2)
Jan 19, 2024 80 CERTIFICATE OF SERVICE by Samsung Bioepis, CO., LTD., for Defendant Samsung Bioepis Co. Ltd.'s Production of Documents Bates SB150000606 to SB150001335. (Law, Sandra) (Entered: 01/19/2024) (3)
Jan 19, 2024 81 CERTIFICATE OF SERVICE by Samsung Bioepis, CO., LTD., for Defendant Samsung Bioepis Co. Ltd.'s Objections and Responses to Regeneron Pharmaceutical Inc.'s 2nd Set of Requests for Production. (Law, Sandra) (Entered: 01/19/2024) (3)
Jan 19, 2024 82 CERTIFICATE OF SERVICE by Samsung Bioepis, CO., LTD., for Defendant Samsung Bioepis Co. Ltd.'s Objections and Responses to Regeneron's Amended Notice of 30(b)(6) Deposition of Defendant Samsung Bioepis Co. Ltd.. (Law, Sandra) (Entered: 01/19/2024) (3)
Jan 19, 2024 79 MOTION for Leave to Appear Pro Hac Vice of Teagan Gregory by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Exhibit A) (6)
Jan 19, 2024 79 MOTION for Leave to Appear Pro Hac Vice of Teagan Gregory by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Exhibit B) (1)
Jan 19, 2024 79 MOTION for Leave to Appear Pro Hac Vice of Teagan Gregory by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Attachment WVSB Receipt) (2)
Jan 19, 2024 79 MOTION for Leave to Appear Pro Hac Vice of Teagan Gregory by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Proposed Order) (1)
Jan 19, 2024 78 MOTION for Leave to Appear Pro Hac Vice of Arthur J. Argall III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Exhibit A) (6)
Jan 19, 2024 78 MOTION for Leave to Appear Pro Hac Vice of Arthur J. Argall III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Exhibit B) (1)
Jan 19, 2024 78 MOTION for Leave to Appear Pro Hac Vice of Arthur J. Argall III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Attachment WVSB Receipt) (2)
Jan 19, 2024 78 MOTION for Leave to Appear Pro Hac Vice of Arthur J. Argall III by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/19/2024) (Proposed Order) (1)
Jan 17, 2024 77 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron's Amended Notice of 30(b)(6) Deposition of Defendant Samsung Bioepis Co., Ltd. (Pogue, David) (Entered: 01/17/2024) (2)
Jan 12, 2024 76 CERTIFICATE OF SERVICE by Samsung Bioepis, CO., LTD., for Defendant Samsung Bioepis Co. Ltd.'s First Set of Requests for Production to Regeneron Pharmaceuticals, Inc.. (Law, Sandra) (Entered: 01/12/2024) (3)
Jan 11, 2024 71 ORDER APPROVING APPLICATIONS TO APPEAR PRO HAC VICE. Attorneys Jacob Hartman, Raymond Nimrod, Matthew Traupman, Laura Fairneny, Zachariah Summers, Jennifer Brooks Crozier and Kellie Van Beck are approved to appear pro hac vice in this matter. Signed by Chief District Judge Thomas S Kleeh on 1/11/2024. (jb) (Entered: 01/11/2024) (1)
Jan 11, 2024 72 MOTION for Leave to Appear Pro Hac Vice of Rhochelle Krawetz by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) () (2)
Jan 11, 2024 73 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron's Identification of Patents. (Pogue, David) (Entered: 01/11/2024) (3)
Jan 11, 2024 74 NOTICE by Regeneron Pharmaceuticals, Inc. of Filing of Motion for Transfer of Action to the Northern District of West Virginia Pursuant to 28 U.S.C. 1407 for Coordinated Pretrial Proceedings (Attachments: # 1 Exhibit A)(Pogue, David) (Entered: 01/11/2024) () (5)
Jan 11, 2024 75 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron's Notice of 30(b)(6) Deposition of Defendant Samsung Bioepis Co., Ltd. (Pogue, David) (Entered: 01/11/2024) (2)
Jan 11, 2024 72 MOTION for Leave to Appear Pro Hac Vice of Rhochelle Krawetz by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Exhibit A) (6)
Jan 11, 2024 72 MOTION for Leave to Appear Pro Hac Vice of Rhochelle Krawetz by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Exhibit B) (1)
Jan 11, 2024 72 MOTION for Leave to Appear Pro Hac Vice of Rhochelle Krawetz by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Attachment WVSB Receipt) (2)
Jan 11, 2024 72 MOTION for Leave to Appear Pro Hac Vice of Rhochelle Krawetz by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/11/2024) (Proposed Order) (1)
Jan 11, 2024 74 NOTICE by Regeneron Pharmaceuticals, Inc. of Filing of Motion for Transfer of Action to the Northern District of West Virginia Pursuant to 28 U.S.C. 1407 for Coordinated Pretrial Proceedings (Attachments: # 1 Exhibit A)(Pogue, David) (Entered: 01/11/2024) (Exhibit A) (7)
Jan 9, 2024 68 MOTION for Leave to Appear Pro Hac Vice of Kellie C. Van Beck by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/09/2024) () (3)
Jan 9, 2024 69 ORDER SETTING BRIEFING SCHEDULE ON MOTIONS TO DISMISS AND SETTING SCHEDULE FOR PRELIMINARY INJUNCTION PROCEEDINGS. Signed by Chief District Judge Thomas S Kleeh on 1/9/2024. (cmd) (Entered: 01/09/2024) (4)
Jan 9, 2024 N/A Set/Reset Scheduling Order Deadlines: Motion Hearing set for 5/2/2024 10:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. (cmd) (Entered: 01/09/2024) (0)
Jan 9, 2024 70 Pro Hac Vice Filing Fee paid in the amount of $600.00 for Jacob Hartman, Jennifer M. Brooks Crozier, and Kellie C. Van Beck. Receipt Number 100003801. (jb) (Entered: 01/09/2024) (0)
Jan 9, 2024 68 MOTION for Leave to Appear Pro Hac Vice of Kellie C. Van Beck by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/09/2024) (Exhibit A) (1)
Jan 9, 2024 68 MOTION for Leave to Appear Pro Hac Vice of Kellie C. Van Beck by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/09/2024) (Attachment WVSB Receipt) (2)
Jan 9, 2024 68 MOTION for Leave to Appear Pro Hac Vice of Kellie C. Van Beck by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/09/2024) (Proposed Order) (1)
Jan 8, 2024 66 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron's Second Requests for Production of Documents to Samsung Bioepis Co., Ltd.. (Pogue, David) (Entered: 01/08/2024) (1)
Jan 8, 2024 67 TRANSCRIPT of Proceedings held on 1/5/2024, before Judge Kleeh. Court Reporter/Transcriber Cindy Knecht, Telephone number 304.234.3968. Parties have five business days to file a Notice of Intent to Request Redaction of this transcript. If no such Notice is filed, the transcript will become available via PACER to the public without redaction after 90 calendar days.. Redaction Request due 1/29/2024. Redacted Transcript Deadline set for 2/8/2024. Release of Transcript Restriction set for 4/8/2024. (ck) (Entered: 01/08/2024) (48)
Jan 5, 2024 63 MINUTE ENTRY: ***NOTICE*** THE ATTACHED DOCUMENT IS NOT ACCESSIBLE. IT IS FOR STATISTICAL PURPOSES ONLY. Proceedings held before Chief District Judge Thomas S Kleeh: Status Conference held on 1/5/2024. (Court Reporter Cindy Knecht) (jb) (Entered: 01/05/2024) (0)
Jan 5, 2024 64 MOTION for Leave to Appear Pro Hac Vice of Jennifer M. Brooks Crozier by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/05/2024) () (2)
Jan 5, 2024 65 Pro Hac Vice Filing Fee for Raymond N. Nimrod, Laura L. Fairneny, Matthew A. Traupman and Zachariah B. Summers in the amount of $800.00 paid. Receipt number 100003795. (jb) (Entered: 01/05/2024) (0)
Jan 5, 2024 64 MOTION for Leave to Appear Pro Hac Vice of Jennifer M. Brooks Crozier by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/05/2024) (Exhibit A) (1)
Jan 5, 2024 64 MOTION for Leave to Appear Pro Hac Vice of Jennifer M. Brooks Crozier by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/05/2024) (Attachment WVSB Receipt) (2)
Jan 5, 2024 64 MOTION for Leave to Appear Pro Hac Vice of Jennifer M. Brooks Crozier by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/05/2024) (Proposed Order) (1)
Jan 4, 2024 46 NOTICE of Appearance by Sandra K. Law on behalf of Samsung Bioepis, CO., LTD., (Law, Sandra) (Entered: 01/04/2024) (2)
Jan 4, 2024 47 MOTION to Dismiss for Lack of Jurisdiction Pursuant to Fed. R. Civ. P. 12(b)(2) by Samsung Bioepis, CO., LTD.,. (Law, Sandra) (Entered: 01/04/2024) (5)
Jan 4, 2024 50 RESPONSE in Opposition re 38 MOTION for Alternative Service filed by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Exhibit Exhibits to Samsung Bioepis Co., Ltd's Opposition to Regeneron's Motion for Alternative Service)(Law, Sandra) (Entered: 01/04/2024) () (8)
Jan 4, 2024 51 ***SEALED*** ORDER. Signed by Chief District Judge Thomas S Kleeh on 1/4/2024. (jb) (Copy to counsel of record by email) (Entered: 01/04/2024) (0)
Jan 4, 2024 53 ***SEALED*** ORDER. Signed by Chief District Judge Thomas S Kleeh on 1/4/2024. (jb) (Copy to counsel of record by email) (Entered: 01/04/2024) (0)
Jan 4, 2024 55 MOTION for Leave to Appear Pro Hac Vice of Raymond N. Nimrod by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Raymond N. Nimrod)(Law, Sandra) (Entered: 01/04/2024) () (2)
Jan 4, 2024 56 MOTION for Leave to Appear Pro Hac Vice of Matthew A. Traupman by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Matthew A. Traupman)(Law, Sandra) (Entered: 01/04/2024) () (2)
Jan 4, 2024 57 MOTION for Leave to Appear Pro Hac Vice of Laura L. Fairneny by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Laura L. Fairneny)(Law, Sandra) (Entered: 01/04/2024) () (2)
Jan 4, 2024 58 MOTION for Leave to Appear Pro Hac Vice (Corrected) for Raymond N. Nimrod by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Raymond N. Nimrod)(Law, Sandra) (Entered: 01/04/2024) () (2)
Jan 4, 2024 59 MOTION for Leave to Appear Pro Hac Vice (Corrected) for Matthew A. Traupman by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Matthew A. Traupman)(Law, Sandra) (Entered: 01/04/2024) () (2)
Jan 4, 2024 60 MOTION for Leave to Appear Pro Hac Vice (Corrected) for Laura L. Fairneny by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Laura L. Fairneny)(Law, Sandra) (Entered: 01/04/2024) () (2)
Jan 4, 2024 61 MOTION for Leave to Appear Pro Hac Vice of Zachariah B. Summers by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Zachariah B. Summers)(Law, Sandra) (Entered: 01/04/2024) () (2)
Jan 4, 2024 62 Corporate Disclosure Statement by Samsung Bioepis, CO., LTD.,. (Law, Sandra) (Entered: 01/04/2024) (5)
Jan 4, 2024 59 MOTION for Leave to Appear Pro Hac Vice (Corrected) for Matthew A. Traupman by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Matthew A. Traupman)(Law, Sandra) (Entered: 01/04/2024) (Proposed Order Granting Motion for Pro Hac Vice Admission for Matthew A. Traupma) (1)
Jan 4, 2024 57 MOTION for Leave to Appear Pro Hac Vice of Laura L. Fairneny by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Laura L. Fairneny)(Law, Sandra) (Entered: 01/04/2024) (Proposed Order Granting Motion for Pro Hac Vice Admission for Laura L. Fairneny) (1)
Jan 4, 2024 50 RESPONSE in Opposition re 38 MOTION for Alternative Service filed by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Exhibit Exhibits to Samsung Bioepis Co., Ltd's Opposition to Regeneron's Motion for Alternative Service)(Law, Sandra) (Entered: 01/04/2024) (Exhibit Exhibits to Samsung Bioepis Co., Ltd's Opposition to Regeneron') (29)
Jan 4, 2024 61 MOTION for Leave to Appear Pro Hac Vice of Zachariah B. Summers by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Zachariah B. Summers)(Law, Sandra) (Entered: 01/04/2024) (Proposed Order Granting Motion for Pro Hac Vice Admission for Zachariah B. Summe) (1)
Jan 4, 2024 56 MOTION for Leave to Appear Pro Hac Vice of Matthew A. Traupman by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Matthew A. Traupman)(Law, Sandra) (Entered: 01/04/2024) (Proposed Order Granting Motion for Pro Hac Vice Admission for Matthew A. Traupma) (1)
Jan 4, 2024 58 MOTION for Leave to Appear Pro Hac Vice (Corrected) for Raymond N. Nimrod by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Raymond N. Nimrod)(Law, Sandra) (Entered: 01/04/2024) (Proposed Order Granting Motion for Pro Hac Vice Admission for Raymond N. Nimrod) (1)
Jan 4, 2024 60 MOTION for Leave to Appear Pro Hac Vice (Corrected) for Laura L. Fairneny by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Laura L. Fairneny)(Law, Sandra) (Entered: 01/04/2024) (Proposed Order Granting Motion for Pro Hac Vice Admission for Laura L. Fairneny) (1)
Jan 4, 2024 55 MOTION for Leave to Appear Pro Hac Vice of Raymond N. Nimrod by Samsung Bioepis, CO., LTD.,. (Attachments: # 1 Proposed Order Granting Motion for Pro Hac Vice Admission for Raymond N. Nimrod)(Law, Sandra) (Entered: 01/04/2024) (Proposed Order Granting Motion for Pro Hac Vice Admission for Raymond N. Nimrod) (1)
Jan 3, 2024 43 MOTION to Amend/Correct 14 MOTION for Leave to Appear Pro Hac Vice of Ellen Oberwetter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/03/2024) () (2)
Jan 3, 2024 44 ORDER granting 43 Motion to Amend/Correct 14 Motion for Leave to Appear Pro Hac Vice of Ellen Oberwetter filed by Regeneron Pharmaceuticals, Inc. The motion for leave to appear pro hac vice at [ECF No. 14 ] is DENIED AS MOOT. Signed by Chief District Judge Thomas S Kleeh on 1/3/2024. (jb) (Entered: 01/03/2024) (1)
Jan 3, 2024 45 MOTION for Leave to Appear Pro Hac Vice of Jacob Hartman by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/03/2024) () (2)
Jan 3, 2024 45 MOTION for Leave to Appear Pro Hac Vice of Jacob Hartman by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/03/2024) (Exhibit A) (1)
Jan 3, 2024 45 MOTION for Leave to Appear Pro Hac Vice of Jacob Hartman by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/03/2024) (Attachment WVSB Receipt) (2)
Jan 3, 2024 45 MOTION for Leave to Appear Pro Hac Vice of Jacob Hartman by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 01/03/2024) (Proposed Order) (1)
Jan 3, 2024 43 MOTION to Amend/Correct 14 MOTION for Leave to Appear Pro Hac Vice of Ellen Oberwetter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/03/2024) (Exhibit A) (6)
Jan 3, 2024 43 MOTION to Amend/Correct 14 MOTION for Leave to Appear Pro Hac Vice of Ellen Oberwetter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/03/2024) (Exhibit B) (1)
Jan 3, 2024 43 MOTION to Amend/Correct 14 MOTION for Leave to Appear Pro Hac Vice of Ellen Oberwetter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/03/2024) (Attachment WVSB Receipt) (2)
Jan 3, 2024 43 MOTION to Amend/Correct 14 MOTION for Leave to Appear Pro Hac Vice of Ellen Oberwetter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 01/03/2024) (Proposed Order) (1)
Dec 29, 2023 41 ORDER APPROVING APPLICATIONS TO APPEAR PRO HAC VICE. Kathryn Kayali, Andrew Trask, Shawn Mahaffy, Thomas Fletcher, Renee Griffin, Rebecca Carter, David Berl, Jennalee Beazley, Haylee Bernal Anderson, Natalie Kennedy, Yi Zhang, Tom Yu, Rocco Recce, Priyata Patel, Matthew Sieger, Kathryn Leicht, Elizabeth Weiswasser, Christopher Pepe, Anish Desai and Zhen Lin are permitted to appear pro hac vice in this matter. Signed by Chief District Judge Thomas S Kleeh on 12/29/2023. (jb) (Entered: 12/29/2023) (2)
Dec 29, 2023 42 ORDER SCHEDULING STATUS CONFERENCE. Plaintiff's Emergency Motion for Entry of a Schedule for Preliminary Injunction Proceedings 40 is GRANTED. Status Conference is set for 1/5/2024 10:00 AM in Clarksburg District Judge Courtroom, 2nd Floor before Chief District Judge Thomas S Kleeh. Signed by Chief District Judge Thomas S Kleeh on 12/29/2023. (jb) (Entered: 12/29/2023) (2)
Dec 28, 2023 40 Emergency MOTION for Entry of a Schedule for Preliminary Injunction Proceedings or in the Alternative an Emergency Status Conference by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)(Ruby, Steven) (Entered: 12/28/2023) () (13)
Dec 28, 2023 40 Emergency MOTION for Entry of a Schedule for Preliminary Injunction Proceedings or in the Alternative an Emergency Status Conference by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Proposed Order)(Ruby, Steven) (Entered: 12/28/2023) (Proposed Order) (4)
Dec 22, 2023 38 MOTION for Alternative Service by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Declaration of Andrew E. Goldsmith, # 3 Exhibit A, # 4 Exhibit B, # 5 Exhibit C, # 6 Proposed Order)(Ruby, Steven) (Entered: 12/22/2023) () (5)
Dec 22, 2023 39 CERTIFICATE OF SERVICE by Regeneron Pharmaceuticals, Inc. for Regeneron's First Requests for Production of Documents to Samsung Bioepis Co., Ltd.. (Pogue, David) (Entered: 12/22/2023) (1)
Dec 22, 2023 38 MOTION for Alternative Service by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Declaration of Andrew E. Goldsmith, # 3 Exhibit A, # 4 Exhibit B, # 5 Exhibit C, # 6 Proposed Order)(Ruby, Steven) (Entered: 12/22/2023) (Attachment Memorandum in Support) (23)
Dec 22, 2023 38 MOTION for Alternative Service by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Declaration of Andrew E. Goldsmith, # 3 Exhibit A, # 4 Exhibit B, # 5 Exhibit C, # 6 Proposed Order)(Ruby, Steven) (Entered: 12/22/2023) (Attachment Declaration of Andrew E. Goldsmith) (2)
Dec 22, 2023 38 MOTION for Alternative Service by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Declaration of Andrew E. Goldsmith, # 3 Exhibit A, # 4 Exhibit B, # 5 Exhibit C, # 6 Proposed Order)(Ruby, Steven) (Entered: 12/22/2023) (Exhibit A) (10)
Dec 22, 2023 38 MOTION for Alternative Service by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Declaration of Andrew E. Goldsmith, # 3 Exhibit A, # 4 Exhibit B, # 5 Exhibit C, # 6 Proposed Order)(Ruby, Steven) (Entered: 12/22/2023) (Exhibit B) (5)
Dec 22, 2023 38 MOTION for Alternative Service by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Declaration of Andrew E. Goldsmith, # 3 Exhibit A, # 4 Exhibit B, # 5 Exhibit C, # 6 Proposed Order)(Ruby, Steven) (Entered: 12/22/2023) (Exhibit C) (5)
Dec 22, 2023 38 MOTION for Alternative Service by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Attachment Memorandum in Support, # 2 Attachment Declaration of Andrew E. Goldsmith, # 3 Exhibit A, # 4 Exhibit B, # 5 Exhibit C, # 6 Proposed Order)(Ruby, Steven) (Entered: 12/22/2023) (Proposed Order) (2)
Dec 19, 2023 25 MOTION for Leave to Appear Pro Hac Vice of Natalie C. Kennedy by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) () (2)
Dec 19, 2023 26 MOTION for Leave to Appear Pro Hac Vice of Yi Zhang by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) () (2)
Dec 19, 2023 27 MOTION for Leave to Appear Pro Hac Vice of Tom Yu by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) () (2)
Dec 19, 2023 28 MOTION for Leave to Appear Pro Hac Vice of Rocco Recce by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) () (2)
Dec 19, 2023 29 MOTION for Leave to Appear Pro Hac Vice of Priyata Patel by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) () (2)
Dec 19, 2023 30 MOTION for Leave to Appear Pro Hac Vice of Matthew D. Sieger by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) () (2)
Dec 19, 2023 31 MOTION for Leave to Appear Pro Hac Vice of Kathryn Leicht by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) () (2)
Dec 19, 2023 32 MOTION for Leave to Appear Pro Hac Vice of Elizabeth Weiswasser by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit a, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) () (2)
Dec 19, 2023 33 MOTION for Leave to Appear Pro Hac Vice of Christopher Pepe by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) () (2)
Dec 19, 2023 34 MOTION for Leave to Appear Pro Hac Vice of Anish Desai by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit a, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) () (2)
Dec 19, 2023 35 MOTION for Leave to Appear Pro Hac Vice of Zhen Lin by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) () (2)
Dec 19, 2023 36 Pro Hac Vice Filing Fee in the amount of $2,200.00 paid for Natalie C. Kennedy, Yi Zhang, Tom Yu, Rocco Recce, Priyata Patel, Matthew D. Sieger, Kathryn Leicht, Elizabeth Weiswasser, Christopher Pepe, Anish Desai and Zhen Lin. Receipt Number: 100003787. (jb) (Entered: 12/19/2023) (0)
Dec 19, 2023 34 MOTION for Leave to Appear Pro Hac Vice of Anish Desai by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit a, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Exhibit a) (1)
Dec 19, 2023 34 MOTION for Leave to Appear Pro Hac Vice of Anish Desai by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit a, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Attachment WVSB Receipt) (2)
Dec 19, 2023 34 MOTION for Leave to Appear Pro Hac Vice of Anish Desai by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit a, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Proposed Order) (1)
Dec 19, 2023 28 MOTION for Leave to Appear Pro Hac Vice of Rocco Recce by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Exhibit A) (1)
Dec 19, 2023 28 MOTION for Leave to Appear Pro Hac Vice of Rocco Recce by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Attachment WVSB Receipt) (2)
Dec 19, 2023 28 MOTION for Leave to Appear Pro Hac Vice of Rocco Recce by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Proposed Order) (1)
Dec 19, 2023 30 MOTION for Leave to Appear Pro Hac Vice of Matthew D. Sieger by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Exhibit A) (1)
Dec 19, 2023 30 MOTION for Leave to Appear Pro Hac Vice of Matthew D. Sieger by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Attachment WVSB Receipt) (2)
Dec 19, 2023 30 MOTION for Leave to Appear Pro Hac Vice of Matthew D. Sieger by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Proposed Order) (1)
Dec 19, 2023 35 MOTION for Leave to Appear Pro Hac Vice of Zhen Lin by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Exhibit A) (1)
Dec 19, 2023 35 MOTION for Leave to Appear Pro Hac Vice of Zhen Lin by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Attachment WVSB Receipt) (2)
Dec 19, 2023 35 MOTION for Leave to Appear Pro Hac Vice of Zhen Lin by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Proposed Order) (1)
Dec 19, 2023 26 MOTION for Leave to Appear Pro Hac Vice of Yi Zhang by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Exhibit A) (1)
Dec 19, 2023 26 MOTION for Leave to Appear Pro Hac Vice of Yi Zhang by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Attachment WVSB Receipt) (2)
Dec 19, 2023 26 MOTION for Leave to Appear Pro Hac Vice of Yi Zhang by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Proposed Order) (1)
Dec 19, 2023 25 MOTION for Leave to Appear Pro Hac Vice of Natalie C. Kennedy by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Exhibit A) (1)
Dec 19, 2023 25 MOTION for Leave to Appear Pro Hac Vice of Natalie C. Kennedy by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Attachment WVSB Receipt) (2)
Dec 19, 2023 25 MOTION for Leave to Appear Pro Hac Vice of Natalie C. Kennedy by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Proposed Order) (1)
Dec 19, 2023 31 MOTION for Leave to Appear Pro Hac Vice of Kathryn Leicht by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Exhibit A) (1)
Dec 19, 2023 31 MOTION for Leave to Appear Pro Hac Vice of Kathryn Leicht by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Attachment WVSB Receipt) (2)
Dec 19, 2023 31 MOTION for Leave to Appear Pro Hac Vice of Kathryn Leicht by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Proposed Order) (1)
Dec 19, 2023 33 MOTION for Leave to Appear Pro Hac Vice of Christopher Pepe by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Exhibit A) (1)
Dec 19, 2023 33 MOTION for Leave to Appear Pro Hac Vice of Christopher Pepe by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Attachment WVSB Receipt) (2)
Dec 19, 2023 33 MOTION for Leave to Appear Pro Hac Vice of Christopher Pepe by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Proposed Order) (1)
Dec 19, 2023 27 MOTION for Leave to Appear Pro Hac Vice of Tom Yu by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Exhibit A) (1)
Dec 19, 2023 27 MOTION for Leave to Appear Pro Hac Vice of Tom Yu by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Attachment WVSB Receipt) (2)
Dec 19, 2023 27 MOTION for Leave to Appear Pro Hac Vice of Tom Yu by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Proposed Order) (1)
Dec 19, 2023 29 MOTION for Leave to Appear Pro Hac Vice of Priyata Patel by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Exhibit A) (1)
Dec 19, 2023 29 MOTION for Leave to Appear Pro Hac Vice of Priyata Patel by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Attachment WVSB Receipt) (2)
Dec 19, 2023 29 MOTION for Leave to Appear Pro Hac Vice of Priyata Patel by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Proposed Order) (1)
Dec 19, 2023 32 MOTION for Leave to Appear Pro Hac Vice of Elizabeth Weiswasser by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit a, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Exhibit a) (1)
Dec 19, 2023 32 MOTION for Leave to Appear Pro Hac Vice of Elizabeth Weiswasser by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit a, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Attachment WVSB Receipt) (2)
Dec 19, 2023 32 MOTION for Leave to Appear Pro Hac Vice of Elizabeth Weiswasser by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit a, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/19/2023) (Proposed Order) (1)
Dec 13, 2023 14 MOTION for Leave to Appear Pro Hac Vice of Ellen Oberwetter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) () (2)
Dec 13, 2023 15 MOTION for Leave to Appear Pro Hac Vice of Kathryn Kayali by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) () (2)
Dec 13, 2023 16 MOTION for Leave to Appear Pro Hac Vice of Andrew Trask by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) () (2)
Dec 13, 2023 17 MOTION for Leave to Appear Pro Hac Vice of Shaun Mahaffy by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) () (2)
Dec 13, 2023 18 MOTION for Leave to Appear Pro Hac Vice of Thomas Fletcher by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) () (2)
Dec 13, 2023 19 MOTION for Leave to Appear Pro Hac Vice of Renee M. Griffin by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) () (2)
Dec 13, 2023 20 MOTION for Leave to Appear Pro Hac Vice of Rebecca Carter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) () (2)
Dec 13, 2023 21 MOTION for Leave to Appear Pro Hac Vice of David I. Berl by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) () (2)
Dec 13, 2023 22 MOTION for Leave to Appear Pro Hac Vice of Jennalee Beazley by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) () (2)
Dec 13, 2023 23 MOTION for Leave to Appear Pro Hac Vice of Haylee Bernal Anderson by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) Modified on 12/29/2023 to correct attorney's name. Duplicate docket text from 22 motion (jb). (Entered: 12/13/2023) () (2)
Dec 13, 2023 24 Pro Hac Vice Filing fee: $ 2000.00, receipt number 100003782. (For Attorneys E. Oberwetter, K. Kayali, A. Trask, S. Mahaffy, T. Fletcher, R. Griffin, R. Carter, D. Berl, J. Beazley, and H. Anderson) (snc) (Entered: 12/13/2023) (0)
Dec 13, 2023 23 MOTION for Leave to Appear Pro Hac Vice of Haylee Bernal Anderson by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) Modified on 12/29/2023 to correct attorney's name. Duplicate docket text from 22 motion (jb). (Entered: 12/13/2023) (Exhibit A) (6)
Dec 13, 2023 23 MOTION for Leave to Appear Pro Hac Vice of Haylee Bernal Anderson by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) Modified on 12/29/2023 to correct attorney's name. Duplicate docket text from 22 motion (jb). (Entered: 12/13/2023) (Exhibit B) (1)
Dec 13, 2023 23 MOTION for Leave to Appear Pro Hac Vice of Haylee Bernal Anderson by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) Modified on 12/29/2023 to correct attorney's name. Duplicate docket text from 22 motion (jb). (Entered: 12/13/2023) (Attachment WVSB Receipt) (2)
Dec 13, 2023 23 MOTION for Leave to Appear Pro Hac Vice of Haylee Bernal Anderson by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) Modified on 12/29/2023 to correct attorney's name. Duplicate docket text from 22 motion (jb). (Entered: 12/13/2023) (Proposed Order) (1)
Dec 13, 2023 14 MOTION for Leave to Appear Pro Hac Vice of Ellen Oberwetter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Exhibit A) (6)
Dec 13, 2023 14 MOTION for Leave to Appear Pro Hac Vice of Ellen Oberwetter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Exhibit B) (1)
Dec 13, 2023 14 MOTION for Leave to Appear Pro Hac Vice of Ellen Oberwetter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Attachment WVSB Receipt) (2)
Dec 13, 2023 14 MOTION for Leave to Appear Pro Hac Vice of Ellen Oberwetter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Proposed Order) (1)
Dec 13, 2023 18 MOTION for Leave to Appear Pro Hac Vice of Thomas Fletcher by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Exhibit A) (6)
Dec 13, 2023 18 MOTION for Leave to Appear Pro Hac Vice of Thomas Fletcher by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Exhibit B) (1)
Dec 13, 2023 18 MOTION for Leave to Appear Pro Hac Vice of Thomas Fletcher by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Attachment WVSB Receipt) (2)
Dec 13, 2023 18 MOTION for Leave to Appear Pro Hac Vice of Thomas Fletcher by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Proposed Order) (1)
Dec 13, 2023 17 MOTION for Leave to Appear Pro Hac Vice of Shaun Mahaffy by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Exhibit A) (6)
Dec 13, 2023 17 MOTION for Leave to Appear Pro Hac Vice of Shaun Mahaffy by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Exhibit B) (1)
Dec 13, 2023 17 MOTION for Leave to Appear Pro Hac Vice of Shaun Mahaffy by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Attachment WVSB Receipt) (2)
Dec 13, 2023 17 MOTION for Leave to Appear Pro Hac Vice of Shaun Mahaffy by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Proposed Order) (1)
Dec 13, 2023 22 MOTION for Leave to Appear Pro Hac Vice of Jennalee Beazley by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Exhibit A) (6)
Dec 13, 2023 22 MOTION for Leave to Appear Pro Hac Vice of Jennalee Beazley by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Exhibit B) (1)
Dec 13, 2023 22 MOTION for Leave to Appear Pro Hac Vice of Jennalee Beazley by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Attachment WVSB Receipt) (2)
Dec 13, 2023 22 MOTION for Leave to Appear Pro Hac Vice of Jennalee Beazley by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Proposed Order) (1)
Dec 13, 2023 19 MOTION for Leave to Appear Pro Hac Vice of Renee M. Griffin by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Exhibit A) (6)
Dec 13, 2023 19 MOTION for Leave to Appear Pro Hac Vice of Renee M. Griffin by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Exhibit B) (1)
Dec 13, 2023 19 MOTION for Leave to Appear Pro Hac Vice of Renee M. Griffin by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Attachment WVSB Receipt) (2)
Dec 13, 2023 19 MOTION for Leave to Appear Pro Hac Vice of Renee M. Griffin by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Proposed Order) (1)
Dec 13, 2023 21 MOTION for Leave to Appear Pro Hac Vice of David I. Berl by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Exhibit A) (6)
Dec 13, 2023 21 MOTION for Leave to Appear Pro Hac Vice of David I. Berl by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Exhibit B) (1)
Dec 13, 2023 21 MOTION for Leave to Appear Pro Hac Vice of David I. Berl by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Attachment WVSB Receipt) (2)
Dec 13, 2023 21 MOTION for Leave to Appear Pro Hac Vice of David I. Berl by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Proposed Order) (1)
Dec 13, 2023 20 MOTION for Leave to Appear Pro Hac Vice of Rebecca Carter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Exhibit A) (6)
Dec 13, 2023 20 MOTION for Leave to Appear Pro Hac Vice of Rebecca Carter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Exhibit B) (1)
Dec 13, 2023 20 MOTION for Leave to Appear Pro Hac Vice of Rebecca Carter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Attachment WVSB Receipt) (2)
Dec 13, 2023 20 MOTION for Leave to Appear Pro Hac Vice of Rebecca Carter by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Proposed Order) (1)
Dec 13, 2023 16 MOTION for Leave to Appear Pro Hac Vice of Andrew Trask by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Exhibit A) (6)
Dec 13, 2023 16 MOTION for Leave to Appear Pro Hac Vice of Andrew Trask by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Exhibit B) (1)
Dec 13, 2023 16 MOTION for Leave to Appear Pro Hac Vice of Andrew Trask by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Attachment WVSB Receipt) (2)
Dec 13, 2023 16 MOTION for Leave to Appear Pro Hac Vice of Andrew Trask by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Proposed Order) (1)
Dec 13, 2023 15 MOTION for Leave to Appear Pro Hac Vice of Kathryn Kayali by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Exhibit A) (6)
Dec 13, 2023 15 MOTION for Leave to Appear Pro Hac Vice of Kathryn Kayali by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Exhibit B) (1)
Dec 13, 2023 15 MOTION for Leave to Appear Pro Hac Vice of Kathryn Kayali by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Attachment WVSB Receipt) (2)
Dec 13, 2023 15 MOTION for Leave to Appear Pro Hac Vice of Kathryn Kayali by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Attachment WVSB Receipt, # 4 Proposed Order)(Ruby, Steven) (Entered: 12/13/2023) (Proposed Order) (1)
Dec 8, 2023 9 MOTION for Leave to Appear Pro Hac Vice of Adam Pan by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/08/2023) () (2)
Dec 8, 2023 10 MOTION for Leave to Appear Pro Hac Vice of Andrew Goldsmith by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/08/2023) () (2)
Dec 8, 2023 11 Pro Hac Vice Filing Fee in the amount of $400 paid for Adam Pan and Andrew Goldsmith. Receipt Number 500003437. (jb) (Entered: 12/08/2023) (0)
Dec 8, 2023 12 ORDER granting 10 Motion for Leave to Appear Pro Hac Vice of Andrew Goldsmith. Signed by Chief District Judge Thomas S Kleeh on 12/8/2023. (mas) (Entered: 12/08/2023) (1)
Dec 8, 2023 13 ORDER granting 9 Motion for Leave to Appear Pro Hac Vice of Adam Pan filed by Regeneron Pharmaceuticals, Inc. Signed by Chief District Judge Thomas S Kleeh on 12/8/2023. (jb) (Entered: 12/08/2023) (1)
Dec 8, 2023 9 MOTION for Leave to Appear Pro Hac Vice of Adam Pan by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/08/2023) (Exhibit A) (6)
Dec 8, 2023 9 MOTION for Leave to Appear Pro Hac Vice of Adam Pan by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/08/2023) (Attachment WVSB Receipt) (2)
Dec 8, 2023 9 MOTION for Leave to Appear Pro Hac Vice of Adam Pan by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/08/2023) (Proposed Order) (1)
Dec 8, 2023 10 MOTION for Leave to Appear Pro Hac Vice of Andrew Goldsmith by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/08/2023) (Exhibit A) (1)
Dec 8, 2023 10 MOTION for Leave to Appear Pro Hac Vice of Andrew Goldsmith by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/08/2023) (Attachment WVSB Receipt) (2)
Dec 8, 2023 10 MOTION for Leave to Appear Pro Hac Vice of Andrew Goldsmith by Regeneron Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Attachment WVSB Receipt, # 3 Proposed Order)(Ruby, Steven) (Entered: 12/08/2023) (Proposed Order) (1)
Dec 4, 2023 7 ***SEALED***ORDER GRANTING MOTION FOR LEAVE TO FILE UNDER SEAL [ECF NO. 5 ]. Signed by Chief District Judge Thomas S Kleeh on 12/04/2023. (Copy to counsel) (snc) (Entered: 12/04/2023) (0)
Nov 22, 2023 2 REPORT to USPTO on the filing or determination of an action regarding re 1 Complaint. (hrc) (Entered: 11/22/2023) (3)
Nov 22, 2023 4 VERIFICATION OF ATTORNEY ADMISSION to Attorneys A. Pan, A. Goldsmith, A. Trask, A. Desai, A. Argall, C. Pepe, D. Berl, E. Weiswasser, E. Oberwetter, H. Anderson, J. Beazley, K. Kayali, K. Leicht, M. Sieger, N. Kennedy, P. Patel, R. Carter, R. Griffin, R. Recce, S. Mahaffy, T. Gregory, T. Fletcher, T. Yu, Y. Zhang, and Z. Lin. (hrc) (Entered: 11/22/2023) (1)
Nov 22, 2023 6 Corporate Disclosure Statement by Regeneron Pharmaceuticals, Inc.. (Pogue, David) (Main Document 6 replaced on 11/28/2023) (jb). Modified on 11/28/2023 to replace main document with flattened pdf and modify the docket text (jb). (Entered: 11/22/2023) (2)
Nov 21, 2023 1 Complaint* (1)
Menu